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ABSTRACT 
Development of Novel Methods and their Utilization in the Analysis of the Effect of the  
N-terminus of Human Protein Arginine Methyltransferase 1 Variant 1 on Enzymatic Activity, 
Protein-protein Interactions, and Substrate Specificity 
 
by 
 
 
Brenda Bienka Suh-Lailam, Doctor of Philosophy 
 
Utah State University, 2010 
 
 
Major Professor:  Dr. Joan M. Hevel 
Department:  Chemistry and Biochemistry 
 
 
Protein arginine methyltransferases (PRMTs) are enzymes that catalyze the methylation 
of protein arginine residues, resulting in the formation of monomethylarginine, and/or 
asymmetric or symmetric dimethylarginines.  Although understanding of the PRMTs has grown 
rapidly over the last few years, several challenges still remain in the PRMT field.  Here, we 
describe the development of two techniques that will be very useful in investigating PRMT 
regulation, small molecule inhibition, oligomerization, protein-protein interaction, and substrate 
specificity, which will ultimately lead to the advancement of the PRMT field.  Studies have 
shown that having an N-terminal tag can influence enzyme activity and substrate specificity.  The 
first protocol tackles this problem by developing a way to obtain active untagged recombinant 
PRMT proteins.  The second protocol describes a fast and efficient method for quantitative 
measurement of AdoMet-dependent methyltranseferase activity with protein substrates.  In 
addition to being very sensitive, this method decreases the processing time for the analysis of 
PRMT activity to a few minutes compared to weeks by traditional methods, and generates 3000-
fold less radioactive waste.  We then used these methods to investigate the effect of truncating the 
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NT of human PRMT1 variant 1 (hPRMT1-V1) on enzyme activity, protein-protein interactions, 
and substrate specificity.  Our studies show that the NT of hPRMT1-V1 influences enzymatic 
activity and protein-protein interactions.  In particular, methylation of a variety of protein 
substrates was more efficient when the first 10 amino acids of hPRMT1v1 were removed, 
suggesting an autoinhibitory role for this small section of the N-terminus.  Likewise, as portions 
of the NT were removed, the altered hPRMT1v1 constructs were able to interact with more 
proteins.  Overall, my studies suggest the the sequence and length of the NT of hPRMT1v1 is 
capable of enforcing specific protein interactions.  
 (148 pages) 
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CHAPTER 1 
INTRODUCTION 
Protein arginine methylation is one of over 200 posttranslational modifications that 
increase the structural diversity of proteins and enable organisms to expand upon their limited 
genome.  Methylation of arginine residues in polypeptide chains affects protein-protein, protein-
RNA, and protein-DNA interactions [1].  As a result of this effect on molecular interactions, 
protein arginine methylation is involved in the regulation of numerous cellular processes 
including signal transduction, transcription, DNA repair, mRNA splicing and nuclear/cytoplasmic 
shuttling [2].  Protein arginine methylation has also been implicated in certain disease conditions 
such as cancer, cardiovascular disease, spinal muscular atrophy, multiple sclerosis, and viral 
pathogenesis [2, 3].  In this dissertation, I focus on the family of enzymes that catalyze the 
transfer of methyl groups to arginine residues in target proteins, known as, protein arginine 
methyltransferases (PRMTs).  We use human PRMT1 variant 1 (hPRMT1-V1) as our model.  
Here, we contribute to the advancement of the PRMT field by providing solutions to two 
challenges in the PRMT field: (i) how to obtain tagless PRMTs, and (ii) how to quantitatively 
measure methyl transfer to protein substrates quickly and efficiently.  We also use the tools we 
developed above to address some important questions in the PRMT field. 
The field of protein arginine methylation has only recently emerged from the shadows of 
other posttranslational modifications such as phosphorylation and glycosylation.  Despite 
considerable advancement in the field, it is still unclear how PRMTs choose substrates.  PRMTs 
have a wide range of protein substrates found both in the nucleus and in the cytoplasm.  It is 
therefore important to study how PRMTs achieve substrate specificity.  A large part of the studies 
on substrate specificity thus far have been done with either peptide substrates [4-7] or pieces of 
proteins attached to large tags such as GST [8-10], and very little with protein substrates.  This 
has mainly been due to the fact that most of the available methods for the analysis of protein 
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methylation by PRMTs are time-consuming, and laborious.  This dissertation addresses this 
issue by developing a time efficient and less laborious method for the analysis of the methylation 
of protein substrates [11].  This method impacts not only the PRMT field, but all AdoMet-
dependent methyltransferases as well.  Also, most of the studies on PRMTs have been done using 
recombinant PRMTs purified with tags.  As much as these studies have given a glimpse as to how 
PRMTs work, recent studies have shown that the presence of tags at the N-terminus of PRMTs 
affects their activity and substrate selectivity.  It is therefore essential that when studying PRMTs 
and their substrate selectivity, tagless PRMTs should be employed.  This dissertation also 
addresses this issue by developing a protocol for the cleavage of N-terminal tags off of PRMTs, 
leaving them tagless [12].  It also goes further to investigate the influence of the PRMT1 N-
terminus on enzymatic activity, protein-protein interactions, and substrate specificity. 
In Chapter 3, we developed a protocol for the effective cleavage of N-terminal tags off of 
PRMTs [12].  Before now, cleavage of tagged PRMTs has been problematic, and there is need for 
tagless PRMTs as current studies have shown that the presence of an N-terminal tag affects both 
the activity and substrate specificity of PRMTs [8-10].  In this protocol, a TEV cleavage site is 
introduced in between the tag and the PRMT N-terminus.  After the PRMT has been expressed 
and purified, TEV protease is added to the protein.  TEV protease cleaves the tag leaving only 
one glycine residue at the end of the PRMT protein.  In developing this protocol, we found that in 
order to get efficient cleavage by TEV, a gentle method of cell lysis is required, and so we 
employed lysis by osmotic shock.  This method may also be useful for cleaving other challenging 
target proteins that have the TEV protease recognition site.  This method was then used to purify 
and cleave all the PRMT constructs used in other chapters of this dissertation. 
In Chapter 4, we developed a fast and efficient method for the quantitative measurement 
of s-adenosyl-l-methionine-dependent methyltransferase activity with protein substrates [11].  
Before this assay, the rate of methyl transfer was generally measured by two ways; either by 
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measuring the by-product, AdoHcy or by measuring the methylated product directly.  Many 
assays are available for the measurement of methyl transfer based on both approaches, but these 
methods are either limited to using peptide substrates, require the use of coupling enzymes, 
laborious, or incredibly time-consuming [4, 7, 8, 13-15].  Since the most common way of 
measuring methyl transfer of protein substrates is by measuring the rate of transfer of a 
radiolabeled methyl group from [3H]-AdoMet to the protein, the accuracy and length of time 
employed in this measurement hinges on the ability to separate unreacted [3H]-AdoMet form 
radiolabeled protein.  In this chapter, we report a novel approach for conducting AdoMet-
dependent protein methylation assays (patent-filed) using ZipTip®C4 pipette tips.  The time-
consuming step of separating unreacted [3H]-AdoMet from radiolabeled protein products has 
been drastically shortened.  This method is highly suitable for measuring initial rates under 
saturating conditions, it also has the ability to use nanomolar enzyme concentrations and low 
protein substrate concentrations.  A further benefit of this protocol is the reduction in the volume 
of radioactive waste by more than ~ 3000-fold. 
In Chapter 5, we investigated the influence of the human PRMT1 variant 1 (hPRMT1-
V1) N-terminus on enzymatic activity, protein-protein interactions and substrate selectivity.  It 
has previously been suggested that the N-terminus of PRMTs might influence substrate 
specificity [4].   In this chapter, we employed both truncated and chimeric constructs of 
hPRMT1-V1 and a variety of PRMT1 protein substrates to test for the effect of truncating the N-
terminus and switching the PRMT1 N-terminus with that of PRMT6, on hPRMT1-V1 enzyme 
activity, protein-protein interaction, and substrate specificity.  This study will enhance the current 
understanding of the role of the N-terminus of hPRMT1-V1 and by extension, that of the other 
PRMT family members.  The results from this study confirmed reports that the N-terminus 
influences enzymatic activity and protein-protein interactions with certain protein substrates.  It 
also identified a piece of the N-terminus consisting of the first 10 amino acid residues, which 
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might be involved in regulating enzyme activity and what proteins hPRMT1-V1 interacts with 
in vivo.  Truncating the NT of hPRMT1-V1 at methionine 10 did not affect its substrate specificity 
towards the two recombinant proteins tested nor the endogenous proteins from mouse PRMT1-/- 
ES (embryonic stem) cells.  However, truncating at glutamate 27 did affect substrate specificity 
towards Histone H4 protein.  Also, truncating the NT did not affect the oligomerization of 
hPRMT1-V1. 
In Chapter 6, I describe experimental data and results from completed and uncompleted 
projects.  I also report two interesting observations that need to be further investigated.  In the 
first project I purified six of the seven PRMT1 variants which have C-terminal His6-tags and 
assessed their activity with a peptide substrate.  I found that the best way to get clean C-terminal 
His6-tagged variants was by using a combination of Nickel resin purification followed by heparin 
column purification.  In the second project, we are collaborating with the Kamp Lab 
(Northwestern University) to look at the change in the methyl arginine proteome when A549 lung 
cells are treated with crocidolite asbestos versus cells treated with particulate matter.  So far, we 
have noticed a few differences, but more work still has to be done for conclusions to be reached.  
In the third project, we show that under our experimental conditions, the NT of hPRMT1-V1 is 
not involved in protein-protein interactions with the PRMT1 regulator hCAF1.  However, more 
pulldown experiments still need to be done under more stringent experimental conditions before 
definite conclusions can be made.  The fourth project looks at the interesting observation that no 
linear rate is obtained when the protein substrate GST-MRE11 is methylated in an assay by 
hPRMT1-V1-E27.  Lastly, I discuss an observation where using either Hepes buffer or sodium 
phosphate buffer in an assay alters the activity of hPRMT1-V1 constructs towards certain protein 
substrates. 
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CHAPTER 2 
LITERATURE REVIEW 
S-Adenosyl-L-Methionine  
S-Adenosyl-L-methionine (AdoMet /SAM) is a common co-substrate involved in methyl 
group transfers (Fig. 2-1).  AdoMet is the most widely used enzyme substrate, second only to 
ATP [1]. Methionine adenosyltransferase makes AdoMet from methionine and adenosine 
triphosphate (ATP) [2].  AdoMet is the most expensive metabolic compound made by cells, as 
twelve equivalents of ATP are used in this process [3].  This emphasizes the importance of 
AdoMet in the cell. Several metabolic pathways use AdoMet as a substrate, including; 
transsulfuration, aminopropylation, and transmethylation.  It is also advantageous to the cell to 
make AdoMet because all its breakdown products can be used by the cell [4].  Although AdoMet 
is utilized throughout the body, most of it is made and consumed in the liver [2].  The chemical 
reactivity of the methyl group attached to the methionine sulfur atom in AdoMet allows for its 
donation to an acceptor substrate in transmethylation reactions.  
  
 
 
 
 
 
Figure 2-1.  Structure of s-adenosyl-L-methionine.  This shows the transferable methyl group 
attached to the methionine sulfur making the sulfur atom positively charged.  
Adenosine 
Methionine 
3 
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There are over 40 metabolic reactions that involve a methyl group transfer from 
AdoMet to a variety of substrates such as lipids, nucleic acids, and proteins.  AdoMet is preferred 
over other methyl donors such as tetrahydrofolate (THF) due to the favorable energetics resulting 
from the AdoMet-dependent methyltransfer (-17 kcal mol-1), which is more than twofold that 
from ATP hydrolysis [1].  
AdoMet is essential for cellular growth and repair, and is involved in the biosynthesis of 
numerous mood affecting hormones and neurotransmitters such as dopamine and serotonin.  It is 
sold as a nutritional supplement to help fight depression, liver disease, and osteoarthritic pain.  In 
bacteria, AdoMet is involved in the regulation of genes concerned with methionine or cysteine 
biosynthesis. 
 
S-Adenosyl-L-Methionine Dependent Protein Methylation 
Following translation, most proteins go through some form of modification.  These 
postranslational modifications (PTMs) permit organisms to expand upon the function of their 
limited genomes.  PTMs (glycosylation, phosphorylation, acetylation, methylation, etc.) serve 
numerous functions, one of them being that they serve as signals of cellular communication. 
Protein methylation is a PTM which involves the transfer of a methyl group from a 
methyl donor, predominantly AdoMet, to a methyl acceptor such as protein.  Since most protein 
methylations use AdoMet as the methyl donor of choice, a majority of protein methylations are 
therefore AdoMet-dependent.   
Most methylations occur on nitrogen (N-methylation) and oxygen (O-methylation) atoms 
and to a lesser extent on carbon (C-methylation) and sulfur (S-methylation) atoms of amino acids.  
N-methylation occurs on the nitrogens of lysine, arginine, histidine, glutamine and asparagine, 
with lysine and arginine being the most common targets [5].  When the side chains of lysine and 
arginine are N-methylated, the positive charge of the amino acid is not altered but hydrophobicity 
and steric bulk are increased, which in turn affect protein-protein interactions [5].  While the ε-
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amine of lysine can be mono-, di-, or trimethylated, the guanidino moiety of arginine can only 
be mono or dimethylated.  The enzyme Lysine-specific histone demethylase 1 (LSD1) has been 
reported as being able to catalyze the demethylation of lysine residues on histones [6].  Some 
studies suggest that arginine methylation is also reversible [7], however despite many efforts by 
scientists’, this reversibility catalyzed by the Jumonji domain–containing 6 protein (JMJD6) 
enzyme has not been reproduced.  N-methylation of the imidazole ring of histidine and the side 
chain amide nitrogens of asparagine and glutamine, are not known to be readily reversible under 
physiological conditions.  Conversely, methylation on the nitrogens of DNA is dynamic [8]. 
O-methylation occurs on the side chain carboxylate of glutamate and aspartate, resulting 
in methyl esters.  O-methylation of these residues, conceals the negative charge on the 
carboxylate side chain, and increases hydrophobicity.  O-methylation is readily reversible with 
the modified residues hydrolyzed back to glutamate and aspartate.  In bacterial chemotaxis, 
hydrolysis of protein methyl esters usually serves as a signal [9].   
C- and S-methylations on electron-rich carbon and sulfur atoms have been shown to 
occur in methanogenic bacteria.  These bacteria have the ability to C-methylate arginine and 
glutamine side chains, and also S-methylate the thiolate side chain of cysteine.  X-ray 
crystallographic analysis of the methanogenic bacterial enzyme, methyl-coenzyme M reductase, 
revealed the presence of C-methylated arginine and glutamine, S-methylated cysteine and N-
methylated histidine residues [10]. 
AdoMet-dependent methylation is catalyzed by AdoMet-dependent methyltransferases.  
AdoMet-dependent methyltransferases have been grouped into five classes based on the structure 
of the fold that binds AdoMet and catalyzes methyl group transfer to the bound substrate [11].  
Most of the AdoMet dependent protein methyltransferases belong to Classes I and V.  Class I, 
which is the largest class, has a characteristic seven-stranded β-sheet structure and the protein 
arginine methyltransferases belong to this class.  Class V is dominated by the SET lysine 
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methyltransferases.  Even though AdoMet dependent methyltransferases differ structurally, the 
mechanism by which they catalyze methyl transfer is similar (Fig. 2-2).  Methyl transfer from 
AdoMet to substrate is thought to proceed by an SN2 reaction mechanism (Fig. 2-2).  This 
reaction depends on the polarizability of the target atom which is typically an electron rich 
oxygen, carbon or nitrogen atom, and the strong electrophilic character of the AdoMet methyl 
group.  There is a nucleophilic attack of the methyl group by the target atom. A proton is 
abstracted from the target atom before, during or following methyl transfer.  This eventually leads 
to the release of the AdoMet sulfur moiety forming s-adenosyl-L-homocysteine (AdoHcy/SAH) 
and the methylated product [12, 13] (Fig. 2-2).  The AdoHcy formed is hydrolyzed by SAH 
hydrolase to adenosine and homocysteine [14].  Homocysteine has two possible recycle paths; it 
can either be methylated by methionine synthase to methionine or converted to glutathione [15]. 
 
 
 
 
 
Figure 2-2.  A proposed mechanism of methyl transfer by AdoMet dependent methyltransferases.  
A nucleophile (target atom) attacks the –CH3 group of AdoMet, and a general base abstracts a 
proton from the target atom leading to methyl transfer from AdoMet to target atom. 
 
AdoMet 
AdoHcy 
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Protein Arginine Methylation 
Protein arginine methylation (PRM) is a common post-translational modification that is 
found across the plant and animal kingdoms.  PRM like other post-translational modifications 
increases the structural diversity of proteins and expands upon the function of the limited genome 
of organisms.  Since its discovery 42 years ago [16], protein arginine methylation has been shown 
to be a vital post-translational modification that is used in the control of diverse cellular 
processes. 
Arginine residues within proteins are positively charged and facilitate hydrogen bonding 
and amino-aromatic interactions.  In protein arginine methylation, monomethyl or dimethyl 
groups are added to the guanidino nitrogen atoms of arginine [17].  This results in three main 
species; monomethyl arginine (MMA), asymmetric dimethylarginine (ADMA) or symmetric 
dimethylarginine (SDMA) (Fig. 2-3).  Arginine methylation does not change the positive charge 
on the arginine, but increases its bulkiness, its hydrophobicity and obstructs hydrogen bonding 
[18].  Arginine residues also undergo cleavage by the enzyme peptidylarginine deiminase (PAD) 
generating citrulline [19].  Another enzyme dimethylarginine dimethylaminohydrolase (DDAH) 
converts free methylarginines to ornithine [20]. 
Protein arginine methyltransferases (PRMTs) are the enzymes that catalyze protein 
arginine methylation.  Of the eleven PRMT isoforms that have been identified in humans, six are 
type I (PRMT1, 2, 3, 4, 6 and 8) and three are type II (PRMT5, 7 and 9) [21, 22],  neither 
PRMT10 nor PRMT11 have been classified.  Both type I and II PRMTs form MMA by 
transferring a methyl group from AdoMet to one of the terminal (or ω) guanidino nitrogens of 
arginine.  AdoHcy is a byproduct produced during protein arginine methylation.  Type I PRMTs 
add another methyl group to the previously methylated guanidino nitrogen in MMA to form 
ADMA (Fig. 2-3).  Type II PRMTs add a second methyl group to the unmethylated terminal 
guanidino nitrogen forming SDMA [17].  PRMT7 has been reported to show type III activity in 
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Trypanosoma brucei where it only catalyzes monomethylation of a terminal (ω) guanidino 
nitrogen [23] (Fig. 2-3).  In yeast, a type IV enzyme that only catalyzes the monomethylation of 
the internal guanidino nitrogen (or δ) has been reported [24] (Fig. 2-3).  PRMTs are ubiquitous, 
with homologues found in yeast, mold, Drosophila melanogaster, Caenorhabdtis elegans, sea 
squirt, protozoa, fish and plants [25, 26].  To demonstrate the importance of PRMTs, two mouse 
knockouts were made; PRMT1 null mice died shortly following implantation [27], while PRMT4 
null mice showed impaired cell differentiation [28].  PRMTs play a vital role in cellular processes 
and their span across plant and animal kingdoms indicates an important role for PRMTs in 
biological systems. 
 
 
 
 
Figure 2-3.  Mono- and dimethylation of arginine by PRMTs.  Type I, II and III PRMTs catalyze 
the addition of a monomethyl group to one of the terminal (ω) guanidino nitrogens of arginine 
forming MMA and AdoHcy.  Type I PRMTs catalyze the addition of another methyl group to the 
same guanidino nitrogen forming ADMA, while type II PRMTs add another methyl group to the 
unmodified nitrogen forming SDMA. Type IV PRMTs catalyze the addition of a monomethyl 
group to the internal (δ) guanidino nitrogen forming MMA. 
Arginine 
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Protein Arginine Methyltransferase Family 
 PRMT activity was first described over forty years ago in nuclear thymus extracts from 
calf [16].  Following this, diverse PRMTs were discovered and purified from rat liver, calf brain 
and a variety of cell lines [29-32].  Even though the PRMTs were discovered over forty years 
ago, it wasn’t until twenty nine years later that cDNAs were isolated and cloned [33, 34].  Since 
their discovery, several isoforms of this family have been identified through homology studies, 
database searches, and sequence similarity [26, 35].  So far, eleven PRMT isoforms have been 
identified in humans (Fig. 2-4).  PRMTs contain a common catalytic methyltransferase domain 
which includes a highly conserved core region, and motifs essential for binding to AdoMet and to 
the substrate [36-38].  Although PRMTs have a conserved core, they differ at their N-termini 
which are of variable lengths and contain different domain motifs (Fig. 2-4). 
 PRMT1 was the first PRMT to be discovered and isolated.  PRMT1 is the most 
predominant PRMT in mammalian cells and is responsible for 85% of total protein arginine 
methylation in cells [39].  PRMT1 was first identified as a protein interacting with the leukemia-
associated BTG1 protein and the mammalian intermediate-early TIS21 protein, or with the 
intracytoplasmatic domain of the IFNα receptor [34, 40].  After this, PRMT1 was then identified 
by sequence homology to the yeast arginine methyltransferase Hmt1/Rmt1 [41].  PRMT1 is 
found both in the nucleus and cytoplasm.  The human genome has been shown to have seven 
splice variants of PRMT1 resulting from alternative splicing [42].  These variants differ mainly at 
their N-terminal sequence and tissue localization.  PRMT2 was discovered second by sequence 
similarity to PRMT1 [41, 43] and has been shown to have two splice variants in humans which 
differ only in the second exon [21].  PRMT2 is localized in the nucleus and cytoplasm.  An 
interesting feature of PRMT2 is that it has an SH3 domain at its N-terminus.  Two years after the 
discovery of PRMT1, PRMT3 was identified in a yeast two-hybrid screen as a PRMT1 binding 
partner [44].  To date, only one variant of PRMT3 has been isolated, and has been shown to 
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localize to the cytoplasm [36, 44].  PRMT3 harbors a zinc-finger (ZnF) domain at its N-
terminus and has been shown to use this in substrate recognition (Fig. 2-4).  PRMT4 (CARM1) 
was also identified in a yeast two-hybrid screen interacting with GRIP1 which is a part of the 
p160 family of proteins [45].  One variant of PRMT4 has been isolated and is localized in the 
nucleus[21].  PRMT5 was identified as a Janus tyrosine kinase (Jak2)-binding protein in a two-
hybrid search [46].  PRMT5 has two variants which differ in the first exon [21].  PRMT5 is 
localized in the cytoplasm [47].  PRMT6 was identified by a database search for proteins which 
harbor the characteristic methyltransferase motif [48].  PRMT6 is the smallest member of the 
PRMT family and its subcellular localization is in the nucleus [48].  PRMT6 has been shown to 
automethylate itself [48].  PRMT7 was found in a genetic screen for susceptibility to 
chemotherapeutic cytotoxicity [49].  Unlike other PRMTs, PRMT7 has two catalytic domains 
[50] and is localized both in the nucleus and the cytoplasm [51].  PRMT8 was discovered by a 
database search for proteins which harbor the characteristic methyltransferase motif [52].  
PRMT8 has over 80% sequence identity to PRMT1 and is localized at the plasma membrane.  It 
has a myristoylation (Myr) motif at its N-terminus which facilitates interaction with membrane 
lipids (Fig. 2-4).  PRMT8, just like PRMT6, has the ability to automethylate itself [53].  PRMT9 
was identified through a database search using the sequence of the conserved PRMT methyl 
donor binding domain [54].  PRMT9 harbors an F-box motif at its N-terminus and a ZnF motif at 
its C-terminus.  It is localized in both the nucleus and cytoplasm (Fig. 2-4).  Four splice variants 
have been identified for PRMT9 [21, 54].  PRMT10 was identified by sequence homology to 
PRMT7 [26].  Like PRMT7, PRMT10 has two catalytic domains, but also has an additional TPR 
repeat at its N-terminus.  So far, no catalytic activity or substrates have been shown for PRMT10 
[26, 35].   PRMT11 was identified by sequence similarity search using the sequence of PRMT9 
[26, 35].  PRMT11 is the longest member of the PRMT family described.  It contains an F-box 
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motif at its N-terminus and a nitrous oxidase accessory protein (NosD) motif at its C-terminus 
(Fig. 2-4).  Just like PRMT10, no biochemical functionality has been reported for PRMT11 [35]. 
 
 
 
Figure 2-4.  The PRMT methyltransferase family.  Eleven isoforms of human PRMTs aligned 
based on their core domain and AdoMet methyltransferase binding motifs (black).  The 
subcellular localizations for each isoform is shown; N (nucleus), C (cytoplasm), and PM (Plasma 
membrane).  Localizations marked N/A have not yet been identified. * Denotes the 
automethylation site on the isoform.  PRMT 1 and 4 have also been reported to be automethylated 
but the site of automethylation is not known. 
 
 
PRMT Splice Variants 
In the PRMT family, PRMT1 is the major PRMT present in mammalian cells and tissues, 
and is expressed in all cell types investigated [39, 43, 55].  PRMT1 is localized on chromosome 
19q13.3 of the human genome [21], and has been shown to have seven alternatively spliced 
variants [42].  These variants have a conserved catalytic core domain and only differ at their N-
termini.  They show distinct subcellular localization; variants 1 and 7 are found in the nucleus, 
variant 2 in the cytoplasm, and variants 3, 4, 5, and 6 in both cellular compartments.  The 
exclusive cytoplasmic localization of variant 2 can be explained by the presence of a nuclear 
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export sequence at its N-terminus.  Whilst variants 1, 2, and 3 are expressed ubiquitously, 
variants 4, 5, 6, and 7 are expressed in singular tissues such as pancreas, heart, or muscle.  
Significantly, the relative occurrence of these spliced variants differs when normal and cancerous 
breast tissues are compared.  This makes PRMT1 alternatively spliced variants useful as 
diagnostic markers in breast cancer [56].  Interestingly, it has been suggested that PRMT1 splice 
variants have distinctive activity and substrate specificity even though they only differ at their N-
terminal sequence [42].  However, this study was done using C-terminal His6-tagged enzymes, 
which in collaboration with our lab, were shown to have very low activities.  Also, it used pieces 
of proteins attached to large tags such as GST, which does not correctly reflect physiological 
substrates.  Nonetheless, some variance was observed under these conditions.  Our goal was to 
develop the necessary techniques to test this in the right context, with untagged PRMT enzymes 
and full length proteins. 
PRMT2 has two splice variants, with the second exon  being the only difference between 
them [21].  Unlike PRMT1, both variants encode for the same protein, which is 433 amino acids 
long.  PRMT3 only has one variant described, which encodes for a 531 amino acid long protein 
[21].  Like PRMT3, PRMT4 only has one variant which encodes for a 608 amino acid long 
protein [21].  PRMT5 has two variants described.  These variants vary in the first exon and 
encode for two proteins which differ in length [21].  Only one splice variant has been described 
for PRMT6 and it is predominantly expressed in the kidney, testis and brain.  PRMT7 has one 
variant expressed mainly in dendritic cells, the thymus, and reproductive system.  PRMT8 also 
has only one variant which encodes for a protein which is 394 amino acids in length.  Second to 
PRMT1 is PRMT9 which has four variants described in the human genome.  All four variants 
differ in length and all contain the AdoMet binding domain and an F-box domain at the N-
terminus, except for the shortest isoform which lacks the latter feature.  In addition, the longest 
isoform harbors a ZnF motif at the C-terminal region.  It is only for the shortest isoform of  
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PRMT9 that direct enzymatic activity with peptides and proteins has been described [21]. 
 
The Structure of PRMTs 
The crystal structures of both PRMT1 and PRMT3 have been solved [57, 58].  PRMT1 
was successfully co-crystallized with AdoHcy and a 19 amino acid peptide substrate, R3 
(GGRGGFGGRGGFGGRGGFG), which originates from fibrillarin (Fig. 2-5A).  However, no 
electron density was observed for most of the R3 peptide, mainly that for the substrate arginine 
was seen (Fig. 2-4A).  On the other hand, the PRMT3 structure only had AdoHcy bound  
(Fig. 2-5B). 
From the solved crystal structures, it can be seen that PRMTs have a two domain 
structure composed of an AdoMet-binding domain and a barrel-like domain [57, 58].  The active 
site of PRMTs is situated between these two domains.  The crystal structure of PRMT1 also 
revealed three substrate binding grooves (P1, P2, and P3) which are all acidic and located on the 
surface of PRMT1.  The acidic nature of these grooves gives them the ability to interact with 
substrate arginine residues, hence the possibility that substrates can bind to PRMT1 from 
different directions. 
Although both PRMT1 and PRMT3 structures are available, they have done little to 
improve on the understanding of PRMT substrate preference.  This is partly due to the fact that in 
solving the crystal structure of PRMT1, no electron density was obtained for the NT (only the 
residues after amino acid 40 of the 47 NT residues were observed) even though the substrate 
peptide was crystallized bound to the enzyme, suggestive of a disordered N-terminal tail [57].  
This suggests that the NT does not interact with short substrate peptides nor does it take part in 
placing the substrate arginine in the active site.  However, by employing pieces of proteins the NT 
was shown to affect substrate specificity [42].  Therefore as previously proposed, the NT is 
probably involved in protein-protein interactions and substrate recognition at a site on the protein 
substrate away from the active site. 
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Figure 2-5. Crystal structures of PRMT1 and 3 showing bound cofactor and peptide backbone.  
Structures (A) and (B) show: the X (Blue) and Y (Red) helices which are part of the conserved 
PRMT core, the C-terminus (Magenta), a part of the N-terminal loop (Yellow), s-adenosyl 
homocysteine (AdoHcy) (Orange) and the rest of the PRMT protein (Green).  (C) PRMT1 crystal 
structure showing the P1, P2 and P3 binding grooves with bound peptide backbone.  The P1 (blue 
peptide bound framing the groove) and P2 (blue peptide bound) binding grooves are parallel to 
the X and Y helices respectively and are close to the active site.  P3 (pink peptide bound) is 
perpendicular to the Y helix and is further away from the active site.  The C-terminus (Magenta), 
a part of the N-terminal loop (Yellow), s-adenosyl homocysteine (AdoHcy) (Orange) and the rest 
of the PRMT protein (Green) are also shown. 
A. 
B. 
  
 
19
 
 
 
 
PRMT Protein Substrates 
 PRMTs are ubiquitous, present across plant and animal kingdoms and are known to be 
involved in many cellular processes.  It is therefore only reasonable that they have many protein 
substrates that they act on.  However, it is only in recent years that PRMT protein substrates are 
being identified (Fig. 2-6).  Most of these substrates were identified using proteomic-based mass 
spectrometric techniques, and focused in vitro substrate screens [59].    With such a limited array 
of PRMT substrates, it is therefore not surprising that what determines substrate specificity 
among the different PRMT isoforms is still unclear. 
Typically, PRMTs target proteins containing glycine arginine rich (GAR) motifs with the 
methylated arginines mainly found in ‘RGG’ or ‘RXR’ regions.  This is the case with PRMT1, 
PRMT3, PRMT6 and PRMT8 which generally methylate arginines in GAR motifs.  PRMT4 
however deviates from the GAR motifs and displays a higher degree of specificity.  Since there is 
no apparent motif recognized by PRMT4, it is therefore hard for possible substrates to be 
predicted by database searches.  The type II PRMTs, PRMT5 and PRMT7, on the other hand 
C. 
P1 
P2 P3 
PRMT1 
(PDB ID: 10R8) 
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methylate isolated arginine residues as well as arginines located in GAR motifs.  PRMT9 has 
been identified as a type II PRMT, symmetrically dimethylating MBP (maltose binding protein) 
[54]. 
 
 
 
  
 
Figure 2-6. PRMT protein substrates grouped according to cellular function.  Protein substrates 
are shown for PRMT1-7; substrates are listed below the PRMT responsible for their methylation.  
The grey regions are to help distinguish between substrates on adjacent lines.  Substrates for 
PRMT8-11 are not shown, mainly because their substrates have either not been well characterized 
or not yet known.  The abbreviations stand for: PGC1α, peroxisome proliferator activated 
receptor-γ-coactivator 1α ; ZF5, Zn2+ finger 5; RIP140, Nuclear receptor-interacting protein 1; 
CIRP, cold inducible RNA binding protein; EWS, Ewing Sarcoma; ILF3, interleukin enhancer 
binding factor 3; ZF5, Zn2+ finger 5; TARPP, thymocyte cyclic AMP-regulated phosphoprotein; 
EBNA1(2), Epstein-Barr virus nuclear antigen 1(2); 53BP1, p53-binding protein 1; CBP, CREB 
binding protein; AIB1, Amplified in breast cancer 1; CA150, phosphoCTD-associating protein; 
U1C,U1 snRNP C. 
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No catalytic activity or substrates have been shown for PRMT10 in humans, but in 
plants, PRMT10 demonstrates type I activity, dimethylating Histone H4 in vitro [60].  Due to its 
similarity to PRMT9, it is predicted that PRMT11 might be a type II PRMT, but so far no 
biochemical data or functional information have been reported.  Among the eleven PRMTs 
discussed thus far, PRMT1 has the largest number of substrates already identified.  This is not 
surprising since it is the predominant PRMT in mammalian cells and accounts for the majority of 
PRMT activity in vivo [55, 61] (Fig. 2-6). 
 
Biological Significance of PRMTs 
PRMTs are increasingly gaining attention as more and more substrates with central roles 
in cellular processes are being discovered.  With the discovery of these new substrates comes the 
knowledge of the vast number of PRMT-regulated cellular processes.  Some of the cellular 
processes PRMT activity has been implicated in include: signal transduction, DNA repair and 
transcriptional regulation.  Protein arginine methylation primarily regulates cellular processes by 
altering biomolecular interactions like protein-protein interactions [62-69], protein-RNA 
interactions [70-72], and protein-DNA interactions [73-75].  Importantly, the significance of 
PRMTs was established by studies with PRMT knockout mice.  For instance, PRMT1 null mice 
died early in embryonic development suggesting that PRMT1 is required for early post 
implantation mouse development [27, 76], while PRMT 4 null mice which were smaller than 
their wild-type counterparts died shortly after birth [28] and PRMT4 null embryos demonstrated 
delayed endochondral ossification [77].  Both PRMT2 and PRMT3 null mice were viable, but the 
PRMT2 null embryos had fibroblasts which showed increased NF-KappaB activity and more 
resistance to apoptosis than wild type embryos displayed [78].  PRMT3 null embryos were 
smaller than wild type [79]. 
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Signal Transduction 
 Signal transduction is generally directed by posttranslational modifications.  However, 
protein arginine methylation was not considered to be one of them as for a long time, it was 
thought to be irreversible.  Recent findings show that PRMTs play an important role in signal 
transduction. 
 PRMT1 was the first PRMT to be linked to signal transduction [40].  PRMT1 interacts 
with the cytoplasmic region of the type I interferon receptor, where its methyltransferase activity 
leads to an antisense-mediated reduction of PRMT1 levels.  This gives the cells the ability to 
resist cell growth inhibition by IFN.  PRMT1 has also been implicated in the NFAT signaling 
pathway.  Here, PRMT1 methylation of NIP45 facilitates its binding to NFAT, resulting in the 
stimulation of cytokine gene expression [65].  Arginine methylation of FOXO1 by PRMT1 acts 
as an inhibitory modification where it blocks phosphorylation by Akt, as such promotes the 
nuclear localization of FOXO1 [80].  Also, there is evidence that suggests that PRMT1 is 
involved in NGF (Nerve growth factor) receptor signaling [81], insulin signaling and glucose 
metabolism [56].  It has also been suggested that PRMT8 could be involved in signaling due to 
the fact that it has a proline-rich domain that could bind to SH3 domains of numerous proteins 
[53], and a myristoylation motif that facilitates its association with the plasma membrane, 
positioning it to possibly impact a signaling pathway near its start [52]. 
 
DNA Repair 
 The MRE11/Rad50/NBS1 (MRN) complex in mammals plays a vital role in the repair of 
DNA double strand breaks (DSBs).  Methylation of the GAR motif of MRE11 by PRMT1 does 
not affect the assembly of the MRN complex but prevents its recruitment to DSBs [82, 83].  
Another protein, 53BP1 which is also involved in DSB repair has also been shown to be 
methylated by PRMT1, but the effect of this methylation is not yet established [84, 85].  The 
tumor suppressor protein p53 controls crucial cellular processes including DNA repair.  
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Following DNA damage, several signals are generated which lead to the stabilization of p53 
which then functions by activating DNA repair proteins and also inducing the transcription of p21 
which promotes cell cycle arrest. Cell cycle arrest will give the repair proteins time to carry out 
DNA repair for continuous survival of the cell or apoptosis to get rid of the damaged cell.  
Recently, p53 was reported to be methylated by PRMT5 [86].  PRMT5 is important for p53 
expression as the knockdown of PRMT5 was shown to inhibit p53 protein synthesis [87].  Lack 
of p53 protein during DNA damage will seriously handicap the DNA repair response. 
 
Transcriptional Regulation 
 Transcription of proteins can either be activated or repressed, allowing for their 
regulation by several factors.  The ability of PRMTs to methylate histones gives them a way to 
regulate gene expression.  PRMTs have been implicated in the regulation of numerous 
transcription factors including NF-κB, PPARγ, RUNX1, YY1, p53, and E2F1 [88, 89].  Both 
PRMT1 and PRMT4 act as general transcriptional coactivators, activating numerous transcription 
factors [61].  PRMT1 and PRMT4 have been reported to cooperatively enhance steroid hormone 
receptor-mediated reporter gene expression [25].  To further support their synergy, knockdown of 
PRMT1 and PRMT4 resulted in the down regulation of a set of STAT5-controlled genes [90].  
Individually, PRMT1 methylates the transcription factor RUNX1, this prompts the transcription 
repressor, SIN3A, to dissociate promoting RUNX1 transcriptional activity [89]. 
 PRMT5 activity generally results in transcriptional repression, and has been shown to 
function with many repressor complexes such as BRG1, hBRM, BLIMP1 and SNAIL [91-95].  It 
is thought that PRMT5 mediates transcriptional repression by symmetrically dimethylating H3R8 
and H4R3, which will prevent the asymmetric dimethylation of H4R3 by PRMT1, which is 
generally recognized as a transcriptional activating mark [61, 96].  Methylation of H3R2 by 
PRMT6 prevents the methylation of H3K4 as such blocking the recruitment of transcriptional 
activators to the methylated H3K4 mark [97, 98].      
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Biological Regulation of Protein  
Arginine Methylation 
 
Protein arginine methylation is a vital posttranslational modification that is involved in 
diverse cellular processes; therefore it is important that this modification be regulated.  Since 
PRMTs show different subcellular localizations, their activity is limited by this 
compartmentalization.  Also PRMTs in vivo can be regulated by PRMT-binding proteins, 
posttranslational modifications and enzymes that counteract their activity. 
 
Regulation by PRMT-binding proteins 
 PRMT activity has been shown to be regulated by proteins that bind to them (Fig. 2-7).  
The binding of such proteins can result in the activation, inhibition, or even change in the 
substrate specificity of the PRMT.  At least nine of such proteins that interact with PRMTs have 
been described.  PRMT1 activity is stimulated by the related proteins BTG1 and TIS2/BTG2 
towards tested substrates [34].  Another protein hCAF1 which also interacts with BTG1 regulates 
PRMT1 activity [75].  PRMT3 activity is inhibited by the binding of the tumor suppressor DAL-1 
[99].  Recombinant PRMT4 would rather methylate free histone H3, but when in the nucleosomal 
methylation activator complex (NUMAC), PRMT4 acquires the capability to methylate 
nucleosomal histone H3.  Like PRMT4, PRMT5 preferentially methylates H4R3 over H3R8 
which it is in association with the histone-binding protein COPR5 [100].    PRMT5 activity is 
elevated when it is complexed with hSWI/SNF chromatin remodelers, BRG and BRM [96].  
Likewise, PRMT7 activity is enhanced when it is bound to the CTCFL testis-specific factor [101] 
(Fig. 2-7). 
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Figure 2-7. Regulation of PRMT activity by PRMT-binding proteins.  The interaction of PRMT5 
with the proteins BRG and BRM, and PRMT7 with CTCFL protein, enhance PRMT activity, 
while the binding of PRMT3 toDAL-1 decreases PRMT activity.  Other interactions like that of 
PRMT1 with BTG1 and hCAF1, and PRMT4 with the complex NUMAC alter PRMT specificity. 
 
 
Regulation by posttranslational modifications 
A wide array of proteins is regulated by posttranslational modifications and PRMTs are 
most likely not an exception.  PRMT4 homodimerization is inhibited and its catalytic activity 
decreased as a result of phosphorylation by an unknown kinase during mitosis [102].  This is the 
first evidence that PRMTs are regulated by posttranslational modifications.  Also PRMT1, 
PRMT4, PRMT6, and PRMT8 have been shown to be automethylated, but the effect of this 
modification is yet to be revealed [53].   
Usually more than one posttranslational modification occurs on the same protein 
substrate and sometimes neighboring modifications can mask arginine methylation motifs.  
Examples of this are the histone tails which are rich in posttranslational modifications, and the 
combination of these modifications give rise to the histone code.  The methylation of H3R8 by 
PRMT5 is inhibited by H3K9 acetylation [96].  Also, H3K4 trimethylation partially blocks H3R2 
methylation by PRMT6 [98, 103]. 
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Regulation by enzymes that counteract PRMT activity 
 Arginine residues in proteins can be deiminated by peptidyl arginine deiminases (PADs) 
giving rise to citrulline (Fig. 2-8).  PADs only deiminate arginines and not MMA or DMA 
(dimethyl arginine) as earlier thought [104].  Sometimes the activity of PADs results in the 
deimination of PRMT substrate arginines as such interfering with potential methylation.  
Therefore by converting arginine to citrulline, arginine methylation is blocked. 
 
 
 
Figure 2-8. Enzyme activities that counteract protein arginine methylation.  PRMTs dimethylate 
arginines forming ADMA and SDMA.   PAD4 deiminates arginine residues, converting them to 
citrulline, preventing arginine methylation.  JMJD6 is the first arginine demethylase described; it 
targets both ADMA and SDMA on histone tails. 
 
 
 Recently, it was reported that the enzyme JMJD6 (Jumonji domain–containing 6 protein) 
can demethylate dimethylation on H3R2 and H4R3 [7].  It seems that both ADMA and SDMA on 
H4R3 can be demethylated by this enzyme.  This is the first arginine demethylase to be reported; 
hence it is possible that more demethylases of this sort remain to be identified. 
 
Protein Arginine Methylation and Disease 
 Protein arginine methylation has been implicated in a variety of diseases including 
cancer, cardiovascular disease, viral pathogenesis, spinal muscular atrophy and multiple sclerosis.  
PRMTs have a wide range of protein substrates which are found both in the nucleus and 
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cytoplasm.  Therefore considering how widely spread the activities of the PRMTs are, 
incorrect regulation of these enzymes will most likely lead to the emergence of certain disease 
conditions. 
 
Cancer 
Recently, it was demonstrated that mRNA levels for PRMT1 are elevated in certain 
breast cancer cell lines when compared to normal controls [42].  When PRMT1 or its substrate, 
Sam68, is fused directly to the mixed lineage leukemia (MLL) oncogenic protein, in place of its 
normal binding partner EEN, there is an activation of the oncogenic predisposition of MLL.  This 
suggests that the arginine methylation of Sam68 is important in this process [105].  High levels of 
PRMT4 have been identified in resistant prostate and aggressive breast cancer tumors [106, 107].  
It has also been shown that PRMT4 is vital for the estrogen-induced proliferation of the MCF-7 
breast cancer cell line [108].  PRMT5 levels have also been shown to be increased in leukemia  
and lymphoma cells [109], and also in gastric cancer [110]. 
 
Viral Pathogenesis 
 Numerous viral proteins have been shown to be heavily methylated including several 
HIV-1 proteins, Epstein-Barr viral proteins, hepatitis proteins and adenoviral proteins [25].  Most 
of these proteins are substrates of either PRMT1 or PRMT6.  It has been shown that inhibition of 
general PRMT activity increases HIV-1 gene expression and infectivity [111].  Also, it has been 
shown that PRMT activity is important for effective adenovirus infection [112].  Furthermore, it 
has been shown that replication of hepatitis delta is prevented by inhibition of arginine 
methylation [113].  All of this shows that methylation is very important for normal viral 
functioning. 
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Spinal Muscular Atrophy 
 When certain deletions or loss of function occurs in the SMN1 gene, the individual 
suffers from spinal muscular atrophy (SMA) which is an autosomal recessive disease.  SMN is 
required for the assembly of proteins that are involved in RNA metabolism.  This process requires 
that these proteins be arginine methylated.  The Tudor domain of the SMN protein can bind to 
both SDMA and ADMA motifs.  It also interacts with numerous PRMT4 and PRMT5 substrates 
[114, 115].  When the Tudor domain of SMN was examined, point mutations were present in  
SMA patients showing a link between the methylarginine-binding ability of SMN and SMA 
[116]. 
 
Cardiovascular Disease 
The enzyme nitric oxide synthase (NOS) catalyzes the formation of nitric oxide (NO), a 
known vasodilator, from L-arginine.  NO plays multiple roles in the cardiovascular system, and is 
very important for the proper functioning of this system.  When methylated proteins are degraded 
by the proteasome, free MMA, ADMA and SDMA are released.  MMA and ADMA inhibit NOS 
contributing to the development of atherosclerosis [117].  The generation of these NOS inhibitors 
is controlled by the enzymes dimethylarginine dimethylaminohydrolases (DDAHs) which 
metabolize free MMA and ADMA.  It is therefore important that these enzymes (DDAHs) be 
well regulated.  If DDAH is misregulated or PRMT activity is dysfunctional, this might lead to an 
imbalance in the MMA and ADMA pool which might increase the risk of cardiovascular disease 
[118].  This is supported by the fact that Ddah1 knockout mice displayed elevated blood pressure 
and developed vascular pathophysiology [119].  Also, it has been shown that patients with the 
following diseases displayed elevated levels of ADMA; hypercholesterolemia, 
hyperhomocysteinemia, peripheral arterial occlusive disease, hypertension, chronic heart failure 
and coronary artery disease [120]. These observations show that there is a link between high 
levels of ADMA and cardiovascular disease.  To solidify the argument that ADMA concentration 
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plays a role in cardiovascular disease, a study revealed that at the early onset of 
atherosclerosis, ADMA levels were increased.  These studies suggest that ADMA is a potential 
marker for cardiovascular disease [121]. 
 
Multiple Sclerosis 
 Multiple sclerosis (MS) is a disease of the central nervous system which involves 
demyelination of the myelin sheaths that surround and provide protection to the nerve axons.  
Myelin basic protein (MBP) which is one of the main proteins that make up the myelin sheath is a 
PRMT5 substrate.  There is reason to believe that the methylation of MBP is linked to the 
development of MS as MBP methylation was found to be increased in MS patients [122].  It is 
suggested that methylated MBP might serve as an autoantigen, as is the case with methylated Sm 
and coilin proteins in lupus erythematosus [123]. 
 
Detection of Methyl Transfer and Measurement  
of PRMT Activity 
 
 A significant amount of what is currently known about PRMTs was acquired by studying 
the property of recombinant PRMTs.  However, most of these studies have been done using 
recombinant PRMT proteins expressed as tagged fusion proteins.  Several studies have shown 
that, the identity of the N-terminal fusion tag affects the substrate selectivity of PRMTs [53, 54, 
124].  Therefore, to accurately study substrate recognition, it is imperative that a tagless PRMT be 
used.  Cleavage of the fusion tag from PRMTs has proven to be extremely challenging, but 
recently we described a method for the purification of tagless PRMTs for in vitro studies [125]. 
The use of peptide substrates is the most common approach employed in enzymatic 
studies of PRMTs. Generally used in combination with novel assay systems [126-130], these 
studies have provided a first peek of the catalytic mechanism [131-135].  However, there is need 
to translate or confirm these findings with real protein substrates of the protein methyltransferases 
in vivo.  There are three main approaches commonly employed to measure the rate of 
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methyltransfer; the first method measures the by-product, AdoHcy, the second directly 
measures the methylated protein, and the third measures the amount of MMA, and ADMA or 
SDMA in hydrolysed methylated proteins.  These methods are all suitable for the detection of 
methyl transfer but not all are appropriate for the quantitative measurement of PRMT activity. 
Recently, numerous novel assays have been developed geared at measuring AdoHcy 
formation [126-129].  When analyzing methylated proteins, radiolabeled AdoMet (S-adenosyl-L-
[methyl-3H]-methionine; [3H]-AdoMet) is commonly used.   Here, unreacted [3H]-AdoMet is 
separated from radiolabeled protein product by SDS-PAGE.   Another commonly used method is 
by using phosphorimaging/fluorography to detect radiolabeled proteins either in-gel or post-
transfer to a membrane [42, 53].  These methods are good but quite laborious, tedious and time 
consuming.  We recently described a novel method for the analysis of protein methylation which 
is efficient, time-saving, sensitive, and generates less radioactivity compared to other methods 
[136]. 
 
Conclusion 
 Protein arginine methylation is a widespread posttranslational modification that is 
involved in the regulation of a variety of cellular processes.  PRMTs have diverse protein 
substrates ranging from RNA binding proteins, to proteins involved in signaling.  PRMT 
knockout studies show that PRMT activity is vital for cell survival.  However, PRMT activity has 
also been implicated in a number of diseases such as cancer, cardiovascular disease, spinal 
muscular atrophy, and multiple sclerosis.  Even though the understanding of PRMTs has 
advanced in the past few years, there is still little understanding of how substrate specificity is 
achieved among the PRMTs.  Also fascinating is how a single PRMT can recognize numerous 
substrates with such high specificity.  Increased understanding of how this happens will greatly 
impact not only the PRMT field, but biology in general as it will facilitate the discovery of more 
PRMT substrates and PRMT-regulated processes. 
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CHAPTER 3 
 
A PROBLEMATIC TEV-PRMT1 CONSTRUCT IS CLEAVED WHEN OSMOTIC SHOCK IS  
 
EMPLOYED1 
 
 
Abstract 
Protein arginine methyltransferases (PRMTs) are enzymes which are involved in many 
biological processes.  Several studies have shown that the identity of the N-terminal fusion tag 
affects the substrate selectivity of PRMTs.  Therefore, to accurately study substrate recognition, it 
is imperative that a tagless PRMT be used.  However, cleavage of tagged PRMTs has been 
problematic.  We have developed a successful method by which untagged PRMTs can be made 
using a TEV cleavage site at the N-terminal domain.  This method may be useful for cleaving 
other challenging target proteins that have the TEV protease recognition site. 
 
Introduction, Results and Discussion 
Protein arginine methyltransferases or PRMTs are enzymes which catalyze the S-
adenosyl methionine (SAM)-dependent methylation of protein arginine residues.  PRMT activity 
has been implicated in the regulation of numerous cellular processes including sub-cellular 
localization of proteins [1], transcriptional regulation [2] and DNA repair [3], and in certain 
disease conditions such as carcinogenesis [4] and viral pathogenesis [5].  The question of how 
differential substrate selection is achieved between eleven different human PRMT isoforms is a 
major issue in the PRMT field that cannot be answered with recombinant proteins bearing fusion 
tags.  Although they are convenient for affinity-based purification schemes, fusion tags interfere 
with the regulation of enzyme activity and substrate specificity that is controlled by the unique N-
terminal domain of the PRMTs [6-8].  Differential methylation of some PRMT1 substrates is 
                                                 
1 B.B. Suh-Lailam, J.M. Hevel, Efficient cleavage of problematic tobacco etch virus (TEV)-
protein arginine methyltransferase constructs, Anal. Biochem. 387 (2009) 130-2.  
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observed when the N-terminal domain of human PRMT1 (hPRMT1) is altered [6].  More 
importantly, studies with both PRMT8 and PRMT9 show that the type of fusion tag used at the 
N-terminus (GST, FLAG, HA, or HIS) differentially affects methylation of certain protein 
substrates [7, 8].  Unfortunately, moving the tag to the C-terminus results in decreased enzyme 
activity (data not shown).  In view of these findings, it is imperative that untagged PRMTs be 
employed to study PRMT substrate selection and enzyme activity.  However, cleavage of the 
fusion tag from PRMTs has proven to be extremely challenging (this paper and personal 
communications).  Here we describe a method to obtain untagged PRMTs starting with 
recombinant protein bearing a tobacco etch virus (TEV) cleavable affinity tag. 
Many proteases are available commercially for cleaving fusion tags from proteins, for 
example Precision Protease (GE Healthcare), Thrombin and TEV protease.  TEV protease is 
attractive because it can be easily expressed and purified in the lab (making it cost-effective), 
only one alanine residue is left at the end of the protein after TEV cleavage, and the conditions 
for cleavage are mild.  However, we found that in order to get efficient cleavage by TEV, a gentle 
method of cell lysis is required. 
Escherichia coli BL21 (DE3) cells overexpressing HIS6-TEV-hPRMT1 were lysed by 
osmotic shock in the following manner.  Cells (6.5 g) and 10 small glass marbles were added to a 
40 ml centrifuge tube.  Glycerol solution (4 M Glycerol, 50 mM Hepes, pH 8.0) was added to 
yield a total volume of 26 ml.  The centrifuge tubes were mixed for 10 min in a shaker to 
resuspend the cells.  Cells were centrifuged at 8000g for 20 min.  The supernatant was removed 
by slowly decanting.  A few flakes of DNAase and 1ml of a 100 mg/ml lysozyme solution were 
added to the tube and a spatula used to break the cells off the wall of the centrifuge tube.  
Extraction solution (50 mM Hepes, pH 8.0, 0.5 mM phenylmethylsulfonyl fluoride) was added to 
give a final volume of 27 ml.  Tubes were quickly capped and vigorously shaken to rupture the 
cells.  Cells were allowed to sit for 10 min on ice and then centrifuged at 20,000g for 20 min.  
  
 
48
The supernatant was collected and incubated with Ni SepharoseTM 6 Fast Flow (GE 
Healthcare) overnight at 4°C.  HIS6-TEV-hPRMT1 was eluted with a stepwise imidazole gradient 
from 5-500 mM imidazole in 20 mM Hepes, pH 8.0 and 100 mM NaCl.  Fractions were analyzed 
by SDS-PAGE to determine the presence of PRMT1.  Fractions containing the PRMT1 were 
dialyzed into buffer containing 100 mM Hepes at pH 8.0, 200 mM NaCl, 1 mM DTT, 2 mM 
EDTA, and 10% glycerol for 2 hours.  HIS6-TEV protease [9, 10] was added to HIS6-TEV-
hPRMT1 at a ratio of 50 OD280 of TEV to 100 OD280 of HIS6-TEV-hPRMT1.  This mixture was 
dialyzed against dialysis buffer containing 5% glycerol overnight at 4°C.  SDS-PAGE analysis 
showed that HIS6-TEV-hPRMT1 was cleaved efficiently (Figure 1A).  Generally, the amount of 
TEV required for a particular cleavage is empirically determined using a range of target protein: 
protease ratios of 100:1 to 5:1 [10].  TEV protease used in a ratio of 100 OD280 of HIS6-TEV-
hPRMT1 to 1 OD280 of TEV protease resulted in very little cleavage.  We also tried ratios of 
target protein: protease of 10:1 and 2:1.  Approximately 80% of the target protein was cleaved 
using a 10:1 ratio overnight at 4ºC (data not shown).  Further cleavage could be obtained if the 
incubation period was lengthened.  The ratio of 2:1 was optimal for efficient cleavage in a 24 
hour period at 4°C (Figure 3-1A). 
The cleaved protein/TEV protease mixture was dialyzed into buffer containing 20 mM 
Hepes, 100 mM NaCl, 5 mM Imidazole, 0.5 mM PMSF and 10% glycerol.  This protein mixture 
was then applied to a Ni sepharose column and incubated overnight at 4°C.  Both protein 
purification steps can be done on the same Ni sepharose column.  Flow through containing 
cleaved protein was collected and elution buffer containing 20 mM Hepes at pH 8.0, 100 mM 
NaCl, and 150 mM imidazole was used to elute cleaved protein interacting with the Ni resin.  
SDS-PAGE analysis was used to determine the presence of the target protein in both fractions.  
Under these conditions, neither HIS6-TEV nor HIS6-TEV-hPRMT1 was observed in either the 
flow through or the elution.  Fractions were dialyzed into the same dialysis buffer described 
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above with 10% glycerol.  Glycerol was added to the cleaved protein solution to a final 
concentration of 15% and concentrated using an Amicon Centricon plus-20 centrifugal filter 
device with a molecular weight cutoff of 10 kDa.  Protein concentration was determined 
spectrophotometrically using the predicted extinction coefficient of 56435 M-1 cm-1 and the 
protein yield was 0.4 mg/L of cell culture. 
 
 
 
Figure 3-1. Human PRMT1 variant 1 truncated at methionine 11 (hPRMT1v1 M11) before and 
after treatment with TEV protease.  Coomassie stained SDS-PAGE showing HIS6-TEV-
hPRMT1v1 M11 before (lane 1) and after (lane 2) treatment with TEV protease overnight at 4°C.  
In (A), the cells were lysed by osmotic shock. The arrow indicates cleaved hPRMT1v1 M11.  In 
(B) the cells were lysed by sonication.  Cleavage of HIS6-TEV-hPRMT1v1 M11 was not 
observed.  In (C) the cells were lysed by French Press.  Cleavage of HIS6-TEV-hPRMT1v1 M11 
was not observed. 
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The activity of the untagged protein was assessed using a continuous 
spectrophotometric assay previously described in [11] (Figure 3-2).  The assay utilized various 
concentrations of R3 peptide (acetylGGRGGFGGRGGFGGRGGFG), 4 μM hPRMT1, 10 nM 
AdoHcy/MTA nucleosidase, 0.02 μM Adenine Deaminase, 10 nM MnSO4, 250 μM S-
Adenosylmethionine, and 50 mM sodium phosphate buffer pH 7.1.  R3 peptide was used to 
initiate the reactions and a decrease in absorbance at 265 nm was measured.  The Km, app obtained 
for the hPRMT1 construct was 38 + 12 and the Vmax was 3.2 + 0.29.  This shows that the 
untagged construct is active and can be used in PRMT studies. 
 
 
 
 
 
Figure 3-2. Michealis-Menten plot showing the rate of methylation of the R3 peptide by 
untagged hPRMT1v1 M11.  Activity was assessed using a continuous spectrophotometric assay 
[11]. 
 
 
The method described above consistently yielded cleaved protein with three hPRMT1 
variant 1 constructs (full length hPRMT1 variant1, a truncated construct starting from Methionine 
11, and a truncated construct starting from Serine 31) (Figure 3-1A and data not shown).  
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Osmotic shock generally yields less total protein than many other lysis methods, such as 
French press and sonication, which are more commonly used.  However, lysing the cells by either 
French press or sonication resulted in very little if any cleavage of HIS6-TEV-hPRMT1 (Figure 3-
1B and 3-1C). 
In conclusion, we have developed a method by which untagged active PRMTs can be 
successfully obtained and used to study substrate recognition and processing.  When cells 
containing HIS6-TEV-hPRMT1 are lysed by either French press or sonication, no TEV cleavage 
is observed.  Therefore lysing cells by osmotic shock is the key to getting a tagless PRMT.  
Tagless PRMTs can be used in a wide range of studies without worrying about the effect of N-
terminal or C-terminal tags.  We note that in the crystal structure of rat PRMT1, no electron 
density was obtained for the N-terminus suggesting that the N-terminal tail is disordered [12].  It 
is possible that French Press and sonication result in conformations of the N-terminus that are 
inaccessible to TEV protease.  This hypothesis is supported by recent studies [13-15], which 
documented conformational changes in proteins as a result of sonication that can lead to 
aggregation.  Hence for other problematic TEV fusion constructs that show possibly disordered 
N- or C-termini, osmotic shock may facilitate cleavage. 
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CHAPTER 4 
A FAST AND EFFICIENT METHOD FOR QUANTITATIVE MEASUREMENT OF S-
ADENOSYL-L-METHIONINE-DEPENDENT METHYLTRANSFERASE ACTIVITY WITH 
PROTEIN SUBSTRATES2 
 
Abstract 
Modification of protein residues by S-adenosyl-L-methionine (AdoMet)-dependent 
methyltransferases impacts an array of cellular processes.   Here we describe a new approach to 
quantitatively measure the rate of methyl transfer that is compatible with using protein substrates.  
The method relies on the ability of reverse phase resin packed at the end of a pipette tip to quickly 
separate unreacted AdoMet from radiolabeled protein products.  Bound radiolabeled protein 
products are eluted directly into scintillation vials and counted.  In addition to decreasing analysis 
time, the sensitivity of this protocol allows for the determination of initial rate data.  The utility of 
this protocol was shown by generating a Michaelis-Menten curve for the methylation of hnRNP 
K protein by human protein arginine methyltransferase 1, variant 1 (hPRMT1v1) in just over an 
hour.  An additional advantage of this assay is the >3000-fold reduction in radioactive waste over 
existing protocols. 
 
Introduction 
S-Adenosyl-L-methionine (AdoMet)-dependent methyltransferases are a widespread 
class of enzymes present in both prokaryotes and eukaryotes.  Small molecule, nucleic acid and 
protein methyltransferases play important roles in fundamental cellular processes such as 
replication and repair of DNA, transcription, translation, and signal transduction, reviewed  
                                                 
2 B.B. Suh-Lailam, J.M. Hevel, A fast and efficient method for quantitative measurement of s-
adenosyl-L-methionine-dependent methyltransferase activity with protein substrates, 
 Anal. biochem. 398 (2010) 218-24. 
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in [1-4].  Although small molecule and nucleic acid methyltransferases have been well studied, 
the biochemical characterization of protein methyltransferases has advanced more slowly.  The 
use of peptide substrates is the most common approach employed in enzymatic studies of the 
latter [5-10].  Used in conjunction with novel assay systems [8, 10-13], these studies have 
provided a first glimpse of the catalytic mechanism [6, 7, 9, 14, 15].  However, the ability to 
translate or confirm these findings with authentic protein substrates of the protein 
methyltransferases is required to address questions about substrate recognition and specificity in 
vivo. 
 One of the most common protein methylations takes place on the nitrogens of lysine, and 
arginine, with histidine, asparagine, and glutamine being additional, but rare targets [16].  
Although arginine methylation nearly hid in the shadows for more than 30 years [17, 18], a rapid 
succession of reports documenting the biological impact of protein arginine methylation has 
catapulted interest in this posttranslational modification [19-27].  Methylation of the terminal 
guanidino nitrogens of arginine occurs via the protein arginine methyltransferases (PRMTs), a 
family of eleven human enzymes that target both nuclear and cytosolic proteins [28].  The diverse 
set of substrates poses questions about how each PRMT isoform selects substrates.  Two 
approaches to measuring the rate of methyltransfer are to measure the by-product,  
S-adenosylhomocysteine (AdoHcy) or to directly measure the methylated product.  Several novel 
assays have been developed in recent years to measure AdoHcy formation [8, 11-13].  However, 
many of them are limited to using peptide substrates or require the use of coupling enzymes.  
Moreover, many are not compatible when the investigator wishes to determine the inhibitory 
effect of AdoHcy on enzyme activity. 
 The most commonly used method for analyzing methylated proteins is by using 
radiolabeled AdoMet (S-adenosyl-L-[methyl-3H]-methionine; [3H]-AdoMet). SDS-PAGE is used 
to separate unreacted [3H]-AdoMet from radiolabeled protein products.  Although this separation 
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is facile, the detection of the radiolabeled proteins can be quite time consuming, especially if 
the specific activity of the [3H]-AdoMet is low or few residues of the protein are modified.  Two 
methods are described in the literature.  In the first, protein bands in acrylamide are crushed, the 
protein is extracted, and radiolabel associated with the proteins is detected by liquid scintillation 
counting.  This method is quite laborious and tedious, taking on the order of >12 hours to obtain 
efficient retrieval of the proteins from the acrylamide [29].  It is also difficult to assess the 
efficiency of the extraction.  In the second method, radiolabeled proteins are detected, either in-
gel or post-transfer to a membrane, by phosphorimaging/fluorography.  Depending on the number 
of protein residues that can be methylated and the specific activity of the [3H]-AdoMet, this step 
can be several weeks to month long [29, 30].  A standard curve that relates band intensity to 
moles of [3H]-methyl groups must also be done in order to provide quantitative results.  These 
methods are outlined in Scheme 1. 
 Here we report a novel approach for conducting AdoMet-dependent protein methylation 
assays (patent-pending) using ZipTip®C4 pipette tips.  The time-consuming step of separating 
unreacted [3H]-AdoMet from radiolabeled protein products has been drastically shortened 
(Scheme 1).  Unlabeled AdoMet can be added to reactions to furnish saturating concentrations of 
AdoMet while maintaining sufficient detection sensitivity, even at short reaction times.  Coupled 
with the ability to use nanomolar enzyme concentrations and low protein substrate 
concentrations, this protocol is also highly suitable for measuring initial rates under saturating 
conditions.  An added benefit of this protocol is the reduction in the volume of radioactive waste 
by more than ~ 3000-fold.  We demonstrate the utility of this protocol by rapidly generating a 
Michaelis- Menten curve for the methylation of hnRNP K protein by hPRMT1v1 and evaluating 
the effect of a GST tag on PRMT6. 
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Scheme  1. Comparison of currently used protocols for measuring protein methylation with the 
ZipTip protocol.  The total time (*) for analysis by method I reflects conditions used to monitor a 
single end-point, usually under conditions of long enzyme incubation times.  Short reaction times 
required to collect initial rate data necessitate much longer exposure times as shown in this paper.  
The separation of unreacted AdoMet and methylated protein is extremely fast when using the 
ZipTip protocol.  
 
Materials and Methods 
 
Materials 
 ZipTipC4 pipette tips were purchased from Millipore.  The ZipTipC4 is a pipette tip with 
0.6 μL of reversed-phase (C4; silica, 15 μm, 300 Å pore size) chromatography resin fixed at the 
tip.  As noted by the manufacturer’s specifications, these tips have a binding capacity of ~3.3 μg 
protein per tip.  Tagless human PRMT1 variant 1 (hPRMT1v1) was expressed and purified as 
described previously [31].  Histone H3.3 was purchased from New England Biolabs.  His-hnRNP 
K was expressed and purified according to [32]. S-adenosyl-L-[methyl-3H] methionine (specific 
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activity 67.3 Ci/mmol, 0.55 μCi/μl) was purchased from Perkin Elmer.  S-Adenosyl-L-
methionine is more stable in acidic conditions and so is usually provided in dilute acid.  For 
instance,   S-adenosyl-L-[methyl-3H] methionine purchased from Perkin Elmer is provided in 10 
mM sulfuric acid: ethanol (9:1).  Care should be taken to store AdoMet under acidic conditions 
and at low temperatures to minimize hydrolysis and decomposition. 
 
Expression and purification of His-PRMT6  
 E. coli BL21 (Codon plus) cells overexpressing His-PRMT6 were grown in 1 L Luria-
Bertani (LB) broth at 37°C  to an OD600 of 0.6.  Protein expression was induced with 1 mM 
isopropyl-β-D-thiogalactopyranoside at 22°C for 24 hours.  Cells were harvested by 
centrifugation and resuspended in 30 ml loading buffer (50 mM sodium phosphate, 300 mM 
NaCl and 10 mM Imidazole; pH 7.4). Cells were lysed by sonication and cell debris was removed 
by centrifugation at 12,000 g at 4°C for 10 min.  The supernatant was incubated with 3 ml packed 
HisPur cobalt resin (Pierce) at 4°C with end-over-rotation for 3 hours.  The resin was washed 
with ~300 ml of loading buffer.  Bound His-PRMT6 was eluted using a linear imidazole gradient 
from 10–150 mM imidazole in loading buffer.  Fractions showing the presence of His-PRMT6 by 
SDS-PAGE analysis were concentrated using an Amicon Ultra centrifugal filter device with a 30 
kDa molecular weight cutoff.  Buffer was exchanged to buffer containing 50 mM sodium 
phosphate, pH 8.0 according to the manufacturer’s instructions.  His-PRMT 6 was further 
purified using a MonoQ column (GE healthcare).  His-PRMT6 was loaded on to the column in 50 
mM sodium phosphate, pH 8.0.  The column was washed with loading buffer until the absorbance 
at 280 nm approached the baseline. Bound protein was then eluted using a stepwise salt gradient 
from 0 to 1.0 M NaCl.  Fractions were analyzed by SDS and fractions containing His-PRMT6 
were pooled and concentrated as above and buffer exchanged to loading buffer.  Protein was 
stored at -80°C in 10% glycerol.  Approximately 70 μg of purified protein was obtained from 1 L 
of LB broth. 
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Expression and purification of GST-PRMT6  
 E. coli BL21 (Codon plus) cells overexpressing GST-PRMT6 were grown in 1 L LB 
broth at 37°C  to an OD600 of 0.6.  Protein expression was induced with 1 mM isopropyl-β-D-
thiogalactopyranoside at 22°C for 24 hours.  Cells were harvested by centrifugation and 
resuspended in 60 ml ice-cold phosphate buffered saline (PBS). Cells were pelleted by 
centrifugation at 3000 g at 4°C for 10 min, the supernatant was discarded and cells resuspended 
in 60 ml ice-cold PBS. Cells were lysed by sonication and cell debris was removed by 
centrifugation at 12,000 g at 4°C for 10 min.  The supernatant was incubated with 4 ml of GST 
resin slurry (GenScript) at 4°C with end-over-rotation for 3 hours.  The resin was washed with 
~200 ml of PBS and bound GST-PRMT6 eluted using a linear gradient from 0–10 mM reduced 
glutathione in 50 mM Tris-HCL, pH 8.0.  Fractions containing GST-PRMT6 were concentrated 
using an Amicon Ultra centrifugal filter device with a 30 kDa molecular weight cutoff.  Buffer 
was exchanged to buffer containing 50 mM sodium phosphate, pH 8.0 according to the 
manufacturer’s instructions.  GST-PRMT 6 was further purified using a MonoQ column (GE 
healthcare).  GST-PRMT6 was loaded on to the column in 50 mM sodium phosphate, pH 8.0.  
The column was washed with loading buffer until the absorbance at 280 nm approached the 
baseline. Bound protein was then eluted using a stepwise salt gradient from 0 to 1.0 M NaCl.  
Fractions were treated as described above.  Protein was stored at -80°C in 10% glycerol.  
Approximately 100 μg of purified protein was obtained from 1 L of LB broth. 
 
Composition of the methyltransferase reaction 
 for the determination of PRMT activity  
 Assays were performed at 37°C, in a final volume of 125 µl.  Each assay contained 1.0 
μM unlabeled S-adenosyl-L-methionine (AdoMet), 0.06 μCi/μl S-adenosyl-L-[methyl-
3H]methionine (specific activity 67.3 Ci/mmol, 0.55 μCi/μl, Perkin Elmer), 100 mM Hepes,  
0.38 μM bovine serum albumin (BSA), 10% glycerol, 10 nM AdoHcy Nucleosidase (MTAN), 
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and 1.7 μM protein substrate; pH of reaction was 7.6.  The addition of unlabeled AdoMet is to 
ensure that saturating conditions for enzymatic activity are met.  Each reaction was equilibrated at 
37°C for 3 min and then initiated with 100 nM PRMT.  Samples (10 μL) were removed at 
specified times and were analyzed using either SDS-PAGE or ZipTips as discussed below.  
Sampling the reaction over time is preferable because it results in several data points to calculate 
the rate of methyltransfer instead of a single end-point.  It also allows the investigator to 
demonstrate linearity of the response over time. 
 
Separation of [3H]-AdoMet and methylated proteins  
by SDS-PAGE 
 A 10 μL aliquot of the reaction mixture was transferred to 5 μl 4x SDS sample buffer to 
quench the reaction. Unreacted [3H]-AdoMet was separated from the methylated protein products 
by SDS-PAGE.  Protein was transferred to a PVDF membrane.  Transfer efficiency was 
monitored to completion by using prestained protein molecular weight markers that were run in 
adjacent lanes.  Methylation was detected in one of two ways.  The membrane was sprayed with 
EN3HANCE (Perkin Elmer) according to the manufacturer’s instructions, and methylation was 
detected by fluorography [30] after incubating with film for 10 weeks.  Multi Gauge software 
V2.3 (FujiFilms) was used to quantitate band intensity.  Alternatively, protein bands were cut out 
of the membrane and counted in scintillation cocktail on a liquid scintillation counter (LSC).  
 
Separation of [3H]-AdoMet and methylated proteins  
by ZipTips 
 ZipTips were used with solvent compositions and volumes according to the 
manufacturer’s instructions.  Briefly, a 10 μL aliquot of the reaction mixture was transferred to  
6 μl of sample preparation buffer (8 M Guanidine-HCL in 2.5% trifluoroacetic acid (TFA)), 
making the final concentrations 3 M Guanidine-HCL and 0.94% TFA in the mixture.  Guanidine-
HCl denatures the protein and TFA makes the reaction very acidic so that PRMT activity is 
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quenched.  A ZipTipC4 (ZipTip), one for each time point, was then prewetted in wetting buffer 
(75% acetonitrile in deionized H2O) by pipetting up and down twice.  The ZipTip was 
equilibrated by washing twice with equilibration buffer (0.1% TFA in deionized H2O).  Using the 
pre-equilibrated ZipTip, each quenched reaction was pipetted up and down 20 times, so as to bind 
the protein in the reaction to the C4 resin.  The ZipTip was washed 17 times with 10 μl wash 
buffer (0.1% TFA in deionized water) to remove unreacted [3H]-AdoMet.  Bound protein was 
eluted by aspirating and dispensing 10 μl of elution buffer (75% acetonitrile in 0.1%TFA) 10 
times in the same tube.   Eluate was dispensed into 20 ml of scintillation cocktail (Fisher 
Scientific) and counted in a LSC. 
 
Binding and elution efficiencies 
The binding efficiency of hnRNPK to the ZipTips was determined in the following manner.  A 
methylation reaction as described above was incubated at 37°C for 1.5 hours. This sample was 
rapidly desalted on a DG-10 column (Bio-Rad) to remove most of the unreacted AdoMet and 
then further dialyzed in buffer containing 6 M Guanidinium hydrochloride and 100 mM Hepes at 
pH 8.0.  The dialysis buffer (1L) was changed three times.  Volumes (3, 6, and 10 μL) of the 
dialyzed protein were counted directly in scintillation cocktail (representing the total amount of 
methylated protein).  Additional volumes (3, 6, and 10 μL) were applied to three separate 
ZipTips.  Methylated protein eluting from the ZipTips was counted as described above 
(representing the amount of methylation protein retrieved from the column). 
 
Results and Discussion 
 
Separation of unreacted [3H]-AdoMet from 
incorporated tritium using ZipTipC4 
 
 Innovation of the current methodology hinges on accelerating the separation of 
radiolabeled-methylated protein products from unreacted radiolabeled AdoMet.  In order to meet 
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this criterion, we turned our attention to reverse phase (RP) chromatography.  RP resins have 
been used for more than a quarter of a century for the separation of peptides and proteins [33].  
Under denaturing conditions which promote protein unfolding, exposed hydrophobic regions of 
proteins interact with the RP resin.  Although HPLC is a common format when using RP 
chromatography, not all laboratories are equipped with this type of instrument.  Instead we 
focused on an RP-based format which is easy to use and easily obtainable.   The ZipTip houses a 
small amount of C4 RP resin at the end of a pipette tip and is commonly used to desalt proteins 
prior to mass spectroscopy.  To determine if free [3H]-AdoMet can be separated from the 
radiolabeled protein using the ZipTips, a methyltransferase assay was divided in to two equal 
parts; one part was initiated with PRMT1 while the other half was initiated with water (control).  
Both reactions were incubated at 37°C for 12 minutes and then were terminated.  ZipTips with C4 
resin were used to bind the protein in the reaction and then washed and eluted as described in the 
Materials and Methods section.  When the bound protein was eluted, a radioactive peak was 
observed in the reaction initiated with hPRMT1v1 (Fig. 4-1A) and not with water (Fig. 4-1B).  
The background binding of [3H]-AdoMet or its breakdown products was less than 4.5 % of the 
signal under these conditions (Fig. 4-1C).  Additionally, the same amount of background 
radioactivity was observed when the control was performed without protein substrate (data not 
shown).  Baseline separation of the two peaks of radioactivity was observed using 17 washes  
(10 μL each).  These results demonstrate that ZipTips afford a rapid and easy way to separate 
unreacted AdoMet from methylated protein products. 
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Figure 4-1. Elution profiles of 
radioactivity showing the separation 
of unreacted [3H]-AdoMet from 
incorporated 3H-methyl using 
ZipTips.  1.7 μM hnRNP K was 
incubated with 1.0 μM unlabeled 
AdoMet, 0.6 μCi/μl [3H]-AdoMet, 
100 mM Hepes, 0.38 μM BSA, 10% 
glycerol, 10 nM MTAN and 100 nM 
hPRMT1v1, at 37°C for 12 min.  A 10 
μL aliquot was loaded onto a ZipTip 
using a pipetman.  Unreacted [3H]-
AdoMet was removed using 17 
washes and the methylated protein 
eluted using organic solvent.  Panel 
(A) shows the initial peak of 
radioactivity in fractions 1 and 2 
representing unreacted [3H]-AdoMet 
followed by methylated protein in 
fractions 5 and 6.    Panel (B) shows 
the profile from the control reaction 
demonstrating a lack of radioactivity 
in fractions 5 and 6.  When the control 
reaction was run without protein 
substrate, the profile was the same 
(data not shown).  Panel (C) represents 
a zoomed plot of fractions 5 and 6 
from plots (1A) and (1B). 
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Binding and elution efficiencies  
In order to determine the binding and elution efficiencies of hnRNPK to the ZipTips, we 
first prepared a sample of radiolabeled, methylated hnRNPK as described in the materials and 
methods section.  Extensive dialysis was used to remove unreacted AoMet from the reaction 
mixture.  The amount of methylated protein was determined by direct measurement using 
scintillation counting and plotted as a function of sample volume (Figure 4-2).  The same 
volumes of methylated protein were applied to three separate ZipTips, the tips treated as 
described above, and the eluted proteins analyzed by scintillation counting.  Figure 4-2 shows that 
all the radiolabeled protein applied to the column was retrieved from the ZipTips.  The data also 
demonstrate that recovery is linear over a range of protein concentrations.  Additionally, the 
current protocol uses a 75 % acetonitrile in 0.1 % TFA solution to elute protein products from the 
ZipTip (as suggested by the manufacturer).  In order to determine if complete elution of protein 
products was obtained, an additional elution step using 100 % acetonitrile in 0.1 % TFA was 
performed.  No additional radioactivity was observed in this additional elution step (data not 
shown).  This result suggests that the conditions described in the materials and methods section 
are sufficient for complete binding and elution of hnRNPK protein products. 
 
Comparison of the ZipTip assay to currently used protocols 
 We compared commonly used methods for measuring methylation of proteins to the 
ZipTip method.  Three identical methyltransferase assays were set up as described in the 
methods, but different approaches were employed in the separation of unreacted [3H]-AdoMet 
and/or the detection of methylation.  When the reaction products were separated by SDS, 
transferred to a membrane and the membrane incubated with film, it took 10 weeks for 
methylation to be detected by fluorography (Fig. 4-3A).  A two week exposure resulted in a blank 
film (data not shown).  This shows that the sensitivity of this method is low.  Higher sensitivity 
can be obtained by increasing the specific activity of the [3H]-AdoMet but one is limited by the 
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acid that the AdoMet is supplied in, the cost of the radiolabel, and the desire to maintain 
saturating levels of AdoMet in the reaction.  It should be noted that the data in Figure 4-3A were 
obtained using a saturating concentration of protein substrate. This suggests that reactions 
performed using sub-saturating concentrations of protein substrates would likely take months to 
analyze. 
 
 
 
 
Figure 4-2. Measuring the binding and elution efficiencies of hnRNP K protein on ZipTipC4. 
[3H]-Methylated hnRNP K protein, free of any unreacted [3H]-AdoMet, was prepared as 
described in the materials and methods section.  The amount of radioactivity associated with 
hnRNP K was measured and plotted as a function of volume (open circles).  The same volumes of 
hnRNP K were processed using the ZipTip protocol.  The amount of radioactivity associated with 
the eluted protein is shown by the closed circles. 
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Figure 4-3. Monitoring methylation by SDS-PAGE-based methods.  Two identical assays were 
performed and SDS-PAGE used to separate unreacted [3H]-AdoMet from methylated protein 
products.  Reaction mixtures contained 1.0 μM unlabeled AdoMet, 0.6 μCi/μl [3H]-AdoMet, 100 
mM Hepes, 0.38 μM BSA, 10% glycerol, 10 nM MTAN, and 1.7 μM hnRNP K protein; pH 7.6 
in a final volume of 125 µl.  Reactions were carried out at 37°C. Each reaction was equilibrated at 
37°C for 3 min and then initiated with 100 nM hPRMT1v1.  Samples (10 μL) were removed at 
specified times and reactions halted with 5 μL 4X SDS sample buffer.  After SDS-PAGE 
analysis, proteins were transferred to a PVDF membrane.  In (A) the membrane was sprayed with 
EN3HANCE and exposed to film for 10 weeks.  In (B) the protein bands at the appropriate 
molecular weight were cut from the membrane and counted in scintillation cocktail on an LSC.   
Plotted values have background counts associated with a t = 0 timepoint subtracted from them. 
 
 
 
 We found we could decrease the analysis time substantially by measuring the radiolabel 
associated with the PVDF membrane directly by liquid scintillation counting.  After 
electrophoretic transfer, small pieces of the PVDF containing the protein of interest were cut from 
the membrane and transferred to liquid scintillation cocktail and counted on an LSC.  Figure 4-3B 
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shows that this method yielded a linear, time-dependent increase in the amount of counts 
representing an increase in methylated protein with time.  Although this modification decreased 
the amount of time required to analyze protein methylation by several weeks, large amounts of 
contaminated electrophoresis buffers were generated.  Furthermore, the number of assays 
analyzed was limited by the number of gels that could be run. 
 With the third reaction, we employed the ZipTip method as described above and in ~38 
minutes obtained a rate curve (Fig. 4-4A).  Rates observed with the ZipTip protocol were 
comparable to the modified electrophoresis-based protocol (9.6 nMCH3/min vs.  
6.1 nMCH3/min).  Increased counts using the ZipTip protocol are expected because membrane-
bound radiolabeled product is subject to sample adsorbent shielding during counting.  A striking 
difference between the assays was the amount of radiolabeled waste generated; less than 0.3 mL 
of radiolabeled waste was produced with the ZipTip assay versus 1,100 mL of contaminated 
electrophoresis buffers.  To further support the time efficiency of this method, we were able to 
generate an entire Michaelis-Menten curve of the methylation of hnRNP K protein by 
hPRMT1v1 in ~70 minutes (Fig. 4-4B). 
Other methods that are used to directly detect methylated protein products include protein 
hydrolysis and amino acid analysis of released N-methyl amino acids [29], detection by specific 
antibodies [34, 35], and mass spectroscopy [29, 32]. These methods are either labor intensive, 
limited to commercially available antibodies, or require specialized equipment needing technical 
expertise.  Our results show that the ZipTip protocol is superior to current protocols for 
measuring the rate of AdoMet-dependent protein methylation. 
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Figure 4-4. Quantitative measurement of the rate of hPRMT1v1-catalyzed methylation of hnRNP 
K protein using the ZipTip protocol.  Reaction mixtures contained 1.0 μM unlabeled AdoMet, 0.6 
μCi/μl [3H]-AdoMet, 100 mM Hepes, 0.38 μM BSA, 10% glycerol, and 10 nM MTAN; pH 7.6 in 
a final volume of 125 µl.  Reactions were carried out at 37°C. Each reaction was equilibrated at 
37°C for 3 min and then initiated with 100 nM hPRMT1v1.  Samples (10 μL) were removed at 
specified times and processed using the ZipTipC4.  Plotted values have background counts 
associated with a t = 0 timepoint subtracted from them.  Background counts at t = 0 were similar 
to counts obtained from control reactions having either no protein substrate or no enzyme (data 
not shown). (A) The rate of methylation of 1.7 μM hnRNP K protein by hPRMT1v1.  (B) 
Michealis-Menten plot showing the methylation of hnRNP K protein by hPRMT1v1 as a function 
of hnRNP K concentration. 
 
 
 
Comparison of His-PRMT6 and GST-PRMT6  
activities using the ZipTip protocol 
 The ease with which the ZipTip assay is performed will now allow for a more thorough 
investigation of AdoMet-dependent protein methylation.  In particular, we sought to quickly 
investigate the effect of the GST tag on the activity of PRMT6.  Although the GST tag is a 
commonly used fusion tag in PRMT studies, investigations with PRMT1, PRMT8, and PRMT9 
suggest that the N-terminus is involved in regulating methylation activity [29, 36, 37].  When we 
employed the ZipTip protocol to measure the rate of methylation of Histone H3.3 protein by His-
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PRMT6 and GST-PRMT6, the activity of the two fusion proteins differed greatly.  Two 
identical assays were initiated with His-PRMT6 and GST-PRMT6.  We found that His-PRMT6 
had 5-fold higher activity compared to GST-PRMT6 (Fig.4-5) at 500 nM enzyme.  The GST tag 
therefore affects the activity of PRMT6.  This might be due to that fact that GST can form dimers 
which may affect the oligomeric structure of PRMT6 [36]. 
 
 
 
 
Figure 4-5. A comparison of the methylation activities of GST-PRMT6 and His-PRMT6 using 
the ZipTip protocol.  1.7 μM Histone H3.3 was incubated with increasing amounts (0.03 - 0.5 
μM) of GST-PRMT6 (open circles) or His-PRMT6 (closed circles), and 1.0 μM unlabeled 
AdoMet, 0.6 μCi/μl [3H]-AdoMet, 100 mM Hepes, 0.38 μM BSA, 10% glycerol, and 10 nM 
MTAN; pH 7.6 in a final volume of 125 µl.  Reactions were carried out at 37°C. Each reaction 
was equilibrated at 37°C for 3 min and then initiated with the appropriate amount of PRMT6.  
The reactions were processed by ZipTip and counted in scintillation cocktail.  Plotted values have 
background counts associated with a t = 0 timepoint subtracted from them.  Background counts at 
t = 0 were similar to counts obtained from control reactions having either no protein substrate or 
no enzyme (data not shown). 
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Considerations 
 Despite the usefulness and speed of this assay, there are limitations.  For instance, this 
assay is sensitive to reproducible pipetting.  Also attention should be paid to the fact that pipetting 
has to be done slowly since the pipette tips have resin at their ends and this gives a very small 
back pressure.  Pipetting slowly will make sure that buffer moves effectively through the packed 
resin bed.  To save more time when processing many samples, we tried to use a multichannel 
pipette with the ziptips but the pipette did not pull up buffer in all tips at the same speed.  This 
resulted in some samples being washed more than others causing the resulting counts to be 
skewed.   
Although a large majority of proteins are expected to bind to C4 reverse phase resin, 
small protein and peptide substrates may require the use of C18 reverse phase resin which is also 
available in the ZipTip format.  Millipore quotes the capacity of ZipTipC4 at ~3.3 μg; therefore 
care should be taken not to load greater than 3.3 μg when setting up an assay.  The binding and 
elution efficiency for each protein substrate/product can easily be determined as described in this 
paper.  Additionally, because the ZipTip does not offer any separation between different proteins, 
this method is not suitable when a mixture of protein substrates is used.  However, the latter case 
can be addressed using the modified SDS-PAGE protocol and direct counting as described in this 
paper. 
 
Conclusions 
 This study shows that the ZipTipC4 protocol can be used to quantitate AdoMet-dependent 
protein methylation as exemplified by the PRMT family of enzymes used in this work.  It is also 
highly probable that this assay will work for other AdoMet-dependent protein methyltransferases 
such as lysine methyltransferases and carboxylmethyltransferases.  Three characteristics of this 
protocol differentiate it from currently used methods: 1) Separation of unreacted AdoMet and 
methylated protein is extremely fast.  Scheme 1 compares previous protocols to the ZipTip 
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protocol. 2) Because the methylated protein is directly measured using liquid scintillation 
counting, the ability to detect small amounts of radiolabel is increased.  Detection of small 
amounts of methyltransfer during the early part of the reaction allows steady state kinetics to be 
measured with this protocol.  Given the current conditions of the reaction, the lower limit of 
detection of this assay is 0.12 nM CH3/min.  The detection limit could be increased by increasing 
the specific activity of the [3H]-AdoMet in the assay or by using C14-labelled AdoMet.  3) The 
volume of radiolabeled waste generated is decreased by >3000-fold.  Furthermore, given the 
commercial ability of C4 loaded multiwell formats, this protocol could easily be optimized for 
high through-put screens.  The absence of coupling enzymes in this protocol will reduce false 
positive hits, making this protocol highly suitable for screening for modulators of protein 
methyltransferase activity. 
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CHAPTER 5 
ANALYSIS OF THE EFFECT OF THE N-TERMINUS OF hPRMT1-V1 ON ENZYMATIC  
 
ACTIVITY, PROTEIN-PROTEIN INTERACTIONS, AND SUBSTRATE SPECIFICITY 
 
 
Abstract 
 PRMT1 is the predominant PRMT in mammals performing over 85% of the total 
arginine methylation.  It is essential for early embryonic development in mice, and has also been 
implicated in cellular processes such as signal transduction, DNA repair, and transcription 
regulation.  It has previously been suggested that the N-terminus (NT) of PRMTs is involved in 
enzymatic activity, protein-protein interaction, and substrate specificity.  However, some of these 
studies were done using C-terminal tagged PRMTs (which have low activity) and pieces of 
proteins attached to large tags such as glutathione-S-transferase (GST) which do not correctly 
reflect physiological substrates.  Here we describe the effect of truncating the NT of human 
PRMT1 variant 1 (hPRMT1-V1) on enzymatic activity, protein-protein interactions, substrate 
specificity, and oligomerization, using untagged hPRMT1-V1 truncation constructs, chimera and 
full length proteins.  Our results suggest that a small piece of the NT (10 amino acids long) is 
involved in the negative regulation of the enzymatic activity of hPRMT1-V1.  Also, our results 
suggest that the NT is involved in protein-protein interactions and that the 10 amino acid piece at 
the NT might also be involved in regulating hPRMT1-V1 interaction with certain proteins.  
Furthermore, we show that the first 10 amino acids of the NT are not involved in hPRMT1-V1 
oligomerization. 
 
Introduction 
 
The human genome is predicted to have about 30,000 genes, but only about 1.5% of the 
genome codes for proteins [1, 2].  Surprisingly, the proteome contains about two to three orders 
of magnitude more protein isoforms than the number of genes in the genome.  This ability of cells 
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to expand on their limited genome is due to their utilization of processes like alternative 
splicing and posttranslational modification (PTM).  PTMs are chemical modifications that occur 
on proteins after their translation.  More than 5% of human genes encode for the enzymes that 
catalyze these modifications.   Examples of these enzymes include protein kinases, acetylases, 
glycosyl transferases, hydroxylases, ligases, prenyl transferases and methyl-transferases. 
Considering the fact that PTMs alter protein structure and function, the substrate 
specificity and activity of these modification enzymes is crucial for cell function.  However, not 
very much is currently understood about the substrate specificity of most modification enzymes 
and also how their activity is regulated.  That is the case with protein arginine methyltransferases 
(PRMTs) which are enzymes that catalyze the addition of monomethyl or dimethyl groups to the 
guanidino nitrogen atoms of arginines in protein substrates.  The activity of PRMTs results in the 
formation of either monomethyl arginine (MMA), asymmetric dimethylarginine (ADMA) or 
symmetric dimethylarginine (SDMA) in their protein substrates.  A total of nine PRMTs have 
been reported in humans, classified as either type I or type II.  Type I PRMTs (PRMT1, -3, -4, -6, 
and -8) catalyze the formation of MMA and ADMA, while type II PRMTs (PRMT5, 7, and 9) 
catalyze the formation of MMA and SDMA [3].  PRMTs are increasingly gaining attention as 
more and more substrates with central roles in cellular processes such as signal transduction, 
DNA repair, RNA processing, and transcriptional regulation are being discovered [4, 5]. 
However, several questions still remain unanswered in this emerging field.  For example, 
it is still unknown how the activity of PRMT1 (the principal PRMT in mammalian cells) towards 
numerous proteins is regulated.  Although a few studies have shed light on this issue [6, 7], a lot 
still remains to be done for it to be better understood.  Another question of great interest in the 
field of arginine methylation is how substrate specificity is achieved amongst the PRMTs.  A 
consensus sequence for PRMT-dependent methylation has not yet been identified.  Typically, 
PRMTs target proteins containing glycine arginine rich (GAR) motifs with the methylated 
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arginines mainly found in ‘RGG’ or ‘RXR’ regions.  However, some PRMT substrates deviate 
from this model and recent studies have shown that PRMTs also recognize other amino acid 
sequences outside the “RGG” paradigm [8].  So how do PRMTs which have a highly conserved 
active site demonstrate such differences in substrate specificity? 
PRMTs possess a homologous core domain of about 310 amino acids which contains 
both protein substrate and s-adenosyl-L-methionine (AdoMet) binding sites.  Each PRMT 
isoform has a unique N-terminal (NT) extension, while PRMT4 and -7 have additional C-terminal 
extensions.  The role of this unique NT is not well understood, but several studies suggest that it is 
involved in substrate specificity and enzymatic activity.  For instance, it has been suggested that 
distinct substrate specificities exist amongst the seven spliced variants of human PRMT1 which 
only differ at their NT in both sequence and length [9].  Also when the NT of PRMT3 is deleted its 
enzyme activity decreases and its substrate specificity is altered [10, 11].  Likewise, the 
oligomerization of the yeast arginine methyltransferase, Hmt1 is considerably hindered and its 
enzymatic activity decreased when its NT is deleted [12].   
From the crystal structures of PRMT1 and PRMT3, it was determined that these two 
isoforms possess X and Y motifs which are important for activity as truncations in the X helix of 
PRMT1 resulted in inactive proteins [13, 14] and mutation of the conserved methionine 155 in 
the Y helix abolished methyltranseferase activity in PRMT1 [13].  The secondary structures of 
PRMT1, 3, 4 and 6 show the presence of the X, Y and Z motifs. By using sequence alignments 
(CLUSTAL) and prediction algorithms (PSIPRED), the secondary structures of the PRMTs 
without crystal structures can be obtained while that of those with crystal structures (PRMT1 and 
PRMT3) have already been determined (Fig. 5-1).  Since the PRMTs have similar core regions 
and X helices, it is therefore possible that any portion of the NT which influences substrate 
preference is N-terminal to the X helix where their sequences differ.  Therefore if the part of the 
NT that affects enzymatic activity and/or substrate recognition is either absent or substituted, 
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 differences in substrate preference would be observed. 
 
 
 
Figure 5-1.  Sequence and structural homologies between Type I PRMTs.  Secondary structure 
was predicted using PsiPred from the Expasy.org website.  Strictly conserved residues amongst 
all PRMTs are shown in bold face and exist in grey boxes. Arrows indicate residues that were 
observed interacting with the co-substrates in the crystal structures. 
 
In this chapter, we investigate the effect of; (i) truncating the NT of human PRMT1 
variant 1 (hPRMT1-V1) and, (ii) switching the NT of PRMT1 with that of PRMT6 in a protein 
chimera, on methyltranseferase activity, protein-protein interactions, substrate specificity, and 
oligomerization of hPRMT1-V1.  In doing this, both the X and Y helices of all the constructs 
were kept intact (Fig. 5-2).  Overall we observed changes in both activity and substrate specificity 
dependent upon where in the NT the enzyme was truncated.  Also we can deduce from our data 
that the NT of hPRMT1-V1 does not play a crucial role in oligomer formation.  Our study also 
suggests that the first 10 amino acids of the NT of hPRMT1-V1 may function in negatively 
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regulating enzymatic activity and potentially protein-protein interactions with certain protein 
substrates. 
 
 
 
Figure 5-2.  Sequence alignment of hPRMT1-V1 truncation constructs (hPRMT1-V1-M1, 
hPRMT1-V1-M11, hPRMT1-V1-E27, and hPRMT1-V1-S31) and PRMT6 NT: hPRMT1-V1-E27 
chimera.  hPRMT1-V1-M1 is the full length protein starting with methionine 1.  hPRMT1-V1-
M11 is truncated beginning with methionine 11 and so is hPRMT1-V1- E27 which begins with 
glutamate 27.  The entire NT is deleted in hPRMT1-V1-S31 which begins with serine 31.  The 
first 41 amino acids of the PRMT6 NT: hPRMT1-V1-E27 chimera corresponds to the NT of 
PRMT6 and the second half contains hPRMT1-V1 core starting at glutamate 27.  All the 
constructs contain the X, Y and Z helices. 
 
 
Materials and Methods 
 
 
Materials 
 ZipTipc4 pipette tips were purchased from Millipore (described in Ref. [15]).  Histone 
H4 and Histone H3.3 were purchased from New England Biolabs.  Untagged hPRMT1-
V1(accession number: AAF62895) constructs (hPRMT1-V1-M1, hPRMT1-V1-M11, hPRMT1-
V1-E27, and hPRMT1-V1-S31) and His-hnRNP K (accession number: NP_002131) were 
expressed and purified as described previously [15].  GST-MRE11 (accession umber: 
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NP_005581) was obtained from our collaborator Jocelyn Cote (University of Ottawa, Ontario, 
Canada).  S-adenosyl-L-[methyl-3H] methionine (specific activity 70.8 Ci/mmol, 0.55 μCi/μl) was 
purchased from Perkin Elmer.  S-Adenosyl-L-methionine is more stable in acidic conditions and 
so is usually provided in dilute acid.  For instance,   S-adenosyl-L-[methyl-3H] methionine 
purchased from Perkin Elmer is provided in 10 mM sulfuric acid: ethanol (9:1).  Care should be 
taken to store AdoMet under acidic conditions and at low temperatures to minimize hydrolysis 
and decomposition. 
 
The making and purification of the PRMT6 N-terminus:  
hPRMT1-V1 core chimera 
 
The PRMT6 NT (accession umber: NP_060607; residues 1-39) was PCR amplified using 
downstream primers which added an Xho1 restriction site to the 3’ end. In amplifying the 
hPRMT1-V1 core (residues 27-356), the upstream primers added an Xho1 site to the 5’ end while 
the downstream primers added a Pst1 site to the 3’ end. The resulting PCR products were 
digested with an Xho1 restriction enzyme and ligated using the rapid ligation kit from Fermentas. 
The ligation mixture was resolved on a 0.8% agarose gel and the ligation product at the correct 
molecular weight (1.2 Kbp) was gel extracted, using a gel extraction kit from Qiagen. This DNA 
ligation product was then PCR amplified with the addition of both a Kpn1 restriction site and a 
TEV cleavage site to the 3’ end of the PRMT6 segment of the construct. This DNA construct was 
then ligated into a pET 45b vector and E. coli XL-1 blue cells were transformed with the vector 
containing the insert and used to make more copies of the vector. The sequence of the chimera 
was confirmed by DNA sequencing.  E. coli BL21 (DE3) cells overexpressing His-TEV-PRMT6 
NT: hPRMT1-V1-E27 core chimera were grown in 0.5L of LB broth at 37°C to an OD600 of 0.4. 
Protein expression was induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 22° 
for 24 hours. Cells were harvested by centrifugation and lysed by osmotic shock. The protein 
chimera was then purified and cleaved as described in [16]. 
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In vitro methylation of hnRNP K in the determination  
of the composition of the methyltranseferase reaction  
 
 Assays were performed at 37°C, in a final volume of 125 µl.  Each assay contained 500.0 
μM unlabeled S-adenosyl-L-methionine (AdoMet), 0.6 μM S-adenosyl-L-[methyl-3H]methionine, 
100 mM Hepes buffer pH 8.0, 3.03 μM bovine serum albumin (BSA), 10% glycerol, 10 nM 
AdoHcy Nucleosidase (MTAN), and 1.7 μM hnRNP K.  Reactions were each equilibrated at 
37°C for 3 min and then initiated with 6.25 pmol hPRMT1-V1-M1.  The concentrations of BSA 
and AdoMet were then varied as discussed in the results section.  Samples (10 μL) were removed 
at specified times and analyzed by SDS-PAGE.   The methylated protein was then transferred to a 
Polyvinylidene Fluoride (PVDF) membrane and the protein bands cut out and counted in 
scintillation cocktail using a liquid scintillation counter. 
 
Composition of the ZipTip methyltransferase reaction  
for the determination of PRMT activity  
 Assays were performed at 37°C, in a final volume of 125 µl.  Each assay contained 1.0 
μM unlabeled S-adenosyl-L-methionine (AdoMet), 0.06 μCi/μl S-adenosyl-L-[methyl-
3H]methionine (specific activity 70.8 Ci/mmol, 0.55 μCi/μl, Perkin Elmer), 100 mM Hepes, 0.38 
μM bovine serum albumin (BSA), 10% glycerol, 10 nM AdoHcy Nucleosidase (MTAN), and 
indicated concentration of protein substrate; pH of reaction was 8.0.  Reactions were each 
equilibrated at 37°C for 3 min and then initiated with 70 nM PRMT.  Samples (10 μL) were 
removed at specified times and were analyzed using ZipTips as discussed previously [15]. 
 
In vitro methylation of endogenous protein substrates  
from PRMT -/-ES cells 
 The preparation of the PRMT -/-Embryonic stem (ES) cells and the endogenous protein  
substrates (total proteins) from them have previously been described [9].  The obtained cell 
extracts were heat-inactivated at 70ºC for 10 min.  The methylation reactions were performed at 
37°C, in a final volume of 150 µl.  Each reaction was composed of 15 μg of total protein (ES-/- 
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cell lysate), 0.582 μM 3H-[AdoMet], and 70 nM PRMT, in 50 mM sodium phosphate buffer, 
pH 8.0.  Reactions were each equilibrated at 37°C for 3 min and then initiated with the PRMT.  
Samples (30 μL) were removed at specified times and the methylated proteins resolved by SDS-
PAGE.  Proteins were then transferred from gel to PVDF membrane. The membrane was sprayed 
with EN3HANCE (Perkin Elmer) according to the manufacturer’s instructions, and methylated 
proteins were detected by fluorography.  Fluorographs were exposed for four days at -80°C. 
 
Results 
 
Determination of the reaction composition of a  
PRMT assay 
 To determine the reaction composition of our PRMT assay, we looked at the literature 
and found that different studies used different reagent compositions in their PRMT assays, but no 
mention was made as to the selection criteria for each component [9, 17-19].  These reagents 
included dithiothreitol (DTT), detergent (e.g. Nonidet P-40 (NP-40)), potassium acetate (KOAc) 
and bovine serum albumin (BSA).  To find out which of these reagents were actually vital for the 
activity and stability of the PRMT during the reaction, we removed each of these reagents one at 
a time from the reaction and observed the effect on the reaction rate.  We found that the absence 
or presence of KOAc did not make a difference in the reaction rate (data not shown).  It was also 
observed that in the absence of NP-40 or DTT, the reaction rate increased by 2-fold or 1.5-fold 
respectively.  On the other hand, the reaction rate decreased by 2-fold when BSA was absent in 
the reaction mixture (Figure 5-3A).  We concluded that BSA is an important component in the 
reaction mixture for the PRMT assay. 
We then set out to find the lowest concentration of BSA that supports high PRMT 
activity.  Because BSA is only one protein amongst a few other proteins in the reaction mixture, it 
is important to keep its concentration low so that there will be enough room for each protein to 
bind to the ZipTip which has a binding capacity of 3.3 µg.  The effects of three concentrations of 
  
 
84
BSA (1.52 µM, 0.76 µM, and 0.38 µM) lower than the concentration of BSA (3.03 µM) used 
in the previous reaction (Fig. 5-3A) were assessed in a reaction mixture that lacked KOAc, NP-
40, and DTT.  The effect of the absence of BSA on the reaction rate was also assessed.  The 
lowest concentration of BSA tested, 0.38 µM, resulted in a reaction rate comparable to those 
shown by the higher BSA concentrations used (Fig. 5-3B).  We therefore decided to use 0.38 µM 
BSA in the PRMT assays. 
 
 
 
 
 
 
Figure 5-3.  Determining the composition of the PRMT assay.  (A) The activity of 100 μM 
hPRMT1-V1-M1 was assessed in a reaction mixture composed of 1.7 µM hnRNP K protein, 10 
nM MTAN, 1.0 μM AdoMet, 0.6 μM 3H-AdoMet and 100 mM Hepes buffer pH 8.0, 10% 
Glycerol, 0.01% NP-40, 0.5 mM DTT, and 3.03 µM BSA.  The reaction mixture was then 
modified by removing NP-40, DTT, or BSA, and then assessing the activity of hPRMT1-V1-M1 
as described in the materials and methods.  The reaction was initiated with hPRMT1-V1-M1.  (B) 
The same reaction mixture used in (A) but lacking NP-40, and DTT, was utilized, with different 
concentrations of BSA. 
 
A 
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hPRMT1-V1 enzymatic activity and substrate  
specificity can be influenced by the N-terminus 
To determine the effect of the N-terminus (NT) of PRMT1 on enzymatic activity and 
substrate specificity, four untagged human PRMT1 variant 1 (hPRMT1-V1) constructs were 
made including: full length hPRMT1-V1 (hPRMT1-V1-M1), a truncated construct starting from 
Methionine 11 (hPRMT1-V1-M11), a truncated construct starting from glutamate 27  
(hPRMT1-V1-E27), and a truncated construct starting from Serine 31 (hPRMT1-V1-S31).  In 
addition, a protein chimera consisting of the PRMT6 NT (Residues 1 – 39) and the hPRMT1-V1 
core starting from residue E27 (PRMT6 NT: hPRMT1-V1-E27) was made (Fig. 5-2).  If the NT is 
involved in substrate recognition, differences in substrate preference would be observed if the NT 
is absent or substituted.  Alternatively, the NT may be important for overall activity of the 
enzyme.  Therefore, the methyltransferase activity of each untagged hPRMT1-V1 construct was 
assessed in vitro with both peptide and protein substrates.  First, the activity of each untagged 
PRMT was assessed with the R3 peptide (acetylGGRGGFGGRGGFGGRGGFG), using the 
continuous spectrophotometric assay previously described in [20] (Fig. 5-4).  The R3 peptide is a 
widely used PRMT1 substrate that corresponds to residues 13 to 31 of the PRMT1 protein 
B 
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substrate, fibrillarin [13].  The Km, app, Vmax and kcat obtained for each of the hPRMT1 
constructs are shown in Table 1.  hPRMT1-V1-M1, -M11 and -E27 all demonstrated similar 
enzymatic activity with the R3 peptide (Fig. 5-4 A, B and C).  hPRMT1-V1-S31 had about 11-
fold less activity compared to hPRMT1-V1-M1, -M11 and -E27.  Several attempts to obtain good 
data with the chimera using the continuous assay were unsuccessful due to a lot of scatter, but the 
chimera did show enzymatic activity higher than hPRMT1-V1-S31, but less than hPRMT1-V1-
M1, -M11 and -E27 (data not shown). 
To test if the activity observed with peptides can be extended to more physiologically 
relevant substrates, the methyltransferase activity of each hPRMT1-V1 construct was assessed 
with protein substrates in vitro, using the ZipTip assay (previously described in [15]).  hPRMT1-
V1-M11 showed the most activity with the protein substrates tested.  hPRMT1-V1- was second 
with about 14% more activity than hPRMT1-V1-M1 with the hnRNP K protein E27 (fig. 5-5A 
and B).  Due to the low activity demonstrated by hPRMT1-V1-S31 with peptide (Table 1), it was 
not used in the in vitro assays with protein substrates.  The PRMT6 NT: hPRMT1-V1-E27 
chimera, when tested with hnRNP K protein, showed significantly less activity (~11 fold less 
activity when compared to M1, ~18 fold less activity to M11 and ~13 fold less activity to E27) 
than hPRMT1-V1-M1, -M11 and -E27 (fig. 5-5A).  The chimera was not tested with any other 
purified protein substrates due to the low activity. 
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Figure 5-4.  Steady-state analysis of the methylation of the R3 peptide by untagged hPRMT1-V1 
constructs.  Activity was assessed using a continuous spectrophotometric assay (2).  The assay 
utilized various concentrations of R3 peptide [25-200μM] (GRGGFGGRGGFGGRGGFG), 4 μM 
hPRMT1-V1-M1 (hPRMT1-V1-M11), 10nM AdoHcy/MTA nucleosidase (MTAN), 0.02μM 
Adenine Deaminase, 10 nM MnSO4, 250μM S-Adenosylmethionine (SAM), and 50mM sodium 
phosphate buffer pH 7.1.  R3 peptide was used to initiate the reactions. 
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Table 5-1.  Summary of kinetic parameters of the hPRMT1-V1 protein constructs when 
methyltransferase activity with the R3 peptide substrate is assessed using the continuous 
spectrophotometric assay.  
 
 
 
 
 
 
 
 
Figure 5-5.  Steady-state analysis of the kinetics of methylation of protein substrates by untagged 
hPRMT1-V1 constructs.  Activity was assessed using the previously described ZipTip assay 
(Chapter 4).  The assay utilized various concentrations of protein [0.2-10.0 μM] (hnRNP K or 
Histone H4), 70 nM hPRMT1-V1 constructs, 10 nM AdoHcy/MTA nucleosidase (MTAN), 1.0 
μM S-Adenosylmethionine (SAM), 0.06 µCi/µL 3H-AdoMet and 100 mM Hepes buffer pH 8.0.  
The reactions were initiated with the respective hPRMT1-V1 construct. (A) And (B) A plot of the 
Kcat of hPRMT1-V1-M1, -M11, -E27, and PRMT6 NT: hPRMT1-V1-E27 chimera versus the 
concentration of hnRNP K or Histone H4 protein respectively.  The kcat was plotted instead of the 
velocity because the concentration of chimera used in this assay was different from that used for 
the other constructs. 
 
A) 
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PRMT3 has an NT which is 194 amino acids long.  This acidic amino acid rich N-
terminal extension is absent in PRMT1 (fig. 5-6).  Unlike PRMT3 where deletion of the NT at 
residue 183 (fig. 5-6) resulted in a decrease in enzymatic activity and a change in protein 
substrate specificity [10-11], truncating the NT of hPRMT1-V1 at residue 10 increased enzymatic 
activity (kcat, Table 2) towards purified protein substrates used but did not alter substrate 
specificity. 
However, truncating at residue 27 increased substrate specificity towards Histone H4 
protein as evidenced by an order of magnitude increase in kcat/Km.  This result is similar to that 
obtained with PRMT8 where cleavage of its NT (amino acid residues 1 to 60, fig. 5-6) resulted in 
a significant increase in enzyme activity [21] towards the GST-GAR protein.  Adding the PRMT6 
NT to E27 in the chimera significantly decreased the activity of the enzyme (kcat, Table 5-2) 
towards hnRNP K (fig. 5-5A). 
 
B) 
  
 
90
 
 
 
Figure 5-6.  Protein sequences of human PRMT1-V1 (Accession #: AAF62895), PRMT3 
(Accession #: NP_005779), and PRMT8 (Accession #: NP_062828).  The above protein 
sequences are aligned based on the beginning of the core (highlighted in grey).  The arrows 
indicate the amino acid residues where each enzyme was truncated.  This figure shows where 
each PRMT construct was cut and the proximity of the cut to the core. 
 
 
To test if these observations can be broadened to endogenous protein substrates, 
hypomethylated cellular extracts obtained from PRMT1-/-ES cells were utilized in an in vitro 
assay with each of the untagged hPRMT1-V1 constructs as described above in the methods 
section.  The results obtained were consistent with our observations when using purified 
recombinant protein substrates.  hPRMT1-V1-M11 showed the most activity toward endogenous 
protein substrates in both total and cellular fractions followed by hPRMT1-V1-E27 and lastly 
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hPRMT1-V1-M1 (fig. 5-7 lanes 1-12).  Interestingly, [3H]-methyl incorporation was not 
observed with certain substrates at 30mins when hPRMT1-V1-M1 was utilized (fig 5-7A); 
marked with asterisks, compare lanes 4, 8, and 12).  When treated with hPRMT1-V1-S31, no 
[3H]-methyl incorporation was observed with either the total cell lysate or nuclear cell extract 
(data not shown).  PRMT6 NT: hPRMT1-V1-E27 chimera showed low activity towards the 
endogenous protein substrates (fig. 5-7A, lanes l3-16 and fig. 5-7B lanes 13-16).  Overall, minor 
differences were observed in the ability of the full length and truncated constructs to methylate 
endogenous protein substrates.  Also, when the nuclear lysate was methylated, hPRMT1-V1-M1 
showed difficulties in methylating some lower molecular weight bands which hPRMT1-V1-M11 
and  –E27 seemed to methylate with relative ease. 
 
Table 5-2.  Summary of the Michealis constants of each of the hPRMT1-V1 protein constructs 
when the rate of methyltranseferase activity with protein substrates is assessed using the ZipTip 
assay. 
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Figure 5-7. hPRMT1-V1 truncation constructs have different enzymatic activities but not 
substrate specificities towards endogenous proteins.  A) 15 µg of total endogenous protein 
substrates from mouse PRMT1-/- ES cells were incubated with equal amounts of purified 
untagged hPRMT1-V1 truncation constructs in the presence of [3H]-AdoMet.  The resulting 
reactions were separated by SDS-PAGE and proteins transferred to PVDF membranes and 3H-
labeled proteins were visualized by fluorography.  Exposure of fluorographs was at -80 ºC for 4 
days.  Bands at the astericks were not visible at 30 minutes by hPRMT1-V1-M1 and the chimera.  
B)  Cell extracts from mouse PRMT1-/- ES cells were fractionated using the QProteome nuclear 
protein kit from Qiagen.  The nuclear fraction was obtained and dialyzed against 50 mM sodium 
phosphate buffer, pH 7.5.  10 µg of nuclear proteins were used in in vitro methylation assays 
performed same as in (A). 
 
 
 
 
   A) 
      B) 
1      2     3    4     5   6    7    8     9 10 11  12   13     14    15   16 
1       2    3   4   5    6    7    8    9   10 11  12  13  14   15  16       
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Is the N-terminus of hPRMT1-V1 involved in  
protein-protein interactions? 
 
To investigate the involvement of the N-terminus of hPRMT1-V1 in protein-protein 
interactions, each hPRMT1-V1 construct including the chimera was incubated with recombinant 
human proteins immobilized on a glass slide (Invitrogen Protoarray® Human Protein Microarray 
Version 3.0).  The recombinant proteins were expressed using Baculovirus expression in insect 
cells.  The same molar amount of each construct was used to probe the proteins bound to the 
array according to the manufacturer’s instructions.  A PRMT1 antibody (primary) was used to 
detect the presence of bound hPRMT1-V1 constructs and a fluorescent labeled secondary 
antibody was used to probe for the bound PRMT1 antibody.  Each array was scanned using a 
fluorescent microarray scanner and the results analyzed.  PRMT6 NT: hPRMT1-V1-E27 chimera 
interacted with the highest number of proteins, 56, followed by hPRMT1-V1-M11 which 
interacted with 48 proteins.  hPRMT1-V1-E27 interacted with even fewer proteins, 26 and 
hPRMT1-V1-M1 interacted with the least number of proteins, 13 (Table 5-3).  As a control, 
western blot analysis was done using equal molar amounts of the hPRMT1-V1 constructs and the 
PRMT1 primary antibody to show that the antibody detected all the constructs (data not shown). 
 
Table 5-3.  Large scale protein-protein interaction screen with purified recombinant untagged 
hPRMT1-V1-M1, -M11, -E27, and PRMT6 NT: hPRMT1-V1-E27 chimera, using the Invitrogen 
Protoarray® Human Protein Microarray Version 3.0. 
 
 
hPRMT1-V1 
Construct 
Reference 
Number 
Protein Name 
M1 only BC002778.1 Myosin light chain 2, precursor lymphocyte-specific 
 NM_022104.1 chromosome 20 open reading frame 67 (C20orf67) 
 PM_2108 CTL2108 RNP COMPLEX - known Autoantigen 
M1 and E27 NM_007284.1 PTK9L protein tyrosine kinase 9-like (A6-related 
protein) (PTK9L) 
 NM_005522.3 homeo box A1 (HOXA1), transcript variant 1 
 BC019268.1 HMT1 hnRNP methyltransferase-like 2 (S. cerevisiae) 
 BC051843.1 microtubule-associated protein 4, transcript variant 3 
 BC017724.1 FIP1 like 1 (S. cerevisiae) 
 NM_153208.1 hypothetical protein MGC35048 (MGC35048) 
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 NM_002822.1 PTK9 protein tyrosine kinase 9 (PTK9) 
 BC007411.2 diaphanous homolog 1 (Drosophila) 
 NM_058163.1 hypothetical protein DT1P1A10 (DT1P1A10) 
 BC022344.1 PTK9 protein tyrosine kinase 9 
E27 only NM_016355.3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 47 
(DDX47) 
 BC000381.2 TBP-like 1, mRNA (cDNA clone MGC:8389 
IMAGE:2820491) 
 BC017012.1 cDNA clone IMAGE:3914688, partial cds 
 BC038976.1 Rho GTPase activating protein 15 
 PM_2120 CTL2120 SMITH ANTIGEN (SM) - known 
Autoantigen 
 NM_021104.1 ribosomal protein L41 (RPL41) 
 BC013966.2 Homo sapiens family with sequence similarity 64, 
member A 
 NM_032350.3 hypothetical protein MGC11257 (MGC11257) 
 NM_014481.2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2 
(APEX2), nuclear gene encoding mitochondrial protein 
 BC025345.1 mRNA similar to LOC149651 (cDNA clone 
MGC:39393 IMAGE:4862156) 
 NM_005517.2 high-mobility group nucleosomal binding domain 2 
(HMGN2) 
 BC012842.1 hypothetical protein PTD004, mRNA (cDNA clone 
MGC:9241 IMAGE:3861915) 
 NM_130809.2 hypothetical protein MGC12103 (LOC133619) 
 BC050328.1 hypothetical protein MGC48637 
 NM_014251.1 solute carrier family 25, member 13 (citrin) 
(SLC25A13) 
 NM_006002.2 ubiquitin carboxyl-terminal esterase L3 (ubiquitin 
thiolesterase) (UCHL3) 
 NM_006838.1 methionyl aminopeptidase 2 (METAP2) 
M11 only NM_005253.1 Homo sapiens FOS-like antigen 2 (FOSL2) 
Chimera  and 
M11 
NM_015343.1 Homo sapiens dullard homolog (Xenopus laevis) 
(DULLARD) 
 NM_138807.1 Homo sapiens hypothetical protein BC015088 
(LOC132001) 
 BC015569.1 Homo sapiens, Similar to SRp25 nuclear protein, clone 
MGC:22989 IMAGE:3609127 
 NM_004309.2 Homo sapiens Rho GDP dissociation inhibitor (GDI) 
alpha (ARHGDIA) 
 NM_138414.1 Homo sapiens coiled-coil domain containing 101 
(CCDC101) 
 NM_016487.1 Homo sapiens HSPC230 gene (HSPC230) 
 BC005902.1 Homo sapiens biliverdin reductase A 
 NM_004567.2 Homo sapiens 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4 (PFKFB4) 
 BC017347.1 Homo sapiens, clone MGC:29484 IMAGE:5014808 
 CTL2110  
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 BC009423.1 Homo sapiens cDNA clone IMAGE:3538202, with 
apparent retained intron 
 NM_004649.1 Homo sapiens chromosome 21 open reading frame 33 
(C21orf33) 
 BC020749.1 Homo sapiens CD96 molecule, mRNA (cDNA clone 
MGC:22596 IMAGE:4669495) 
 BC016486.1 Homo sapiens, clone MGC:17047 IMAGE:3923237 
 NM_015973.1 Homo sapiens galanin-related peptide (LOC51083) 
 NM_152576.1 Homo sapiens hypothetical protein MGC24103 
(MGC24103) 
 NM_032908.1 Homo sapiens hypothetical protein MGC14407 
(MGC14407) 
 BC033710.1 Homo sapiens, Similar to RAD54B homolog, clone 
MGC:45158 IMAGE:3914364 
 BC031661.1 Homo sapiens hypothetical LOC389458, mRNA 
(cDNA clone IMAGE:5170151) 
 NM_005738.1 Homo sapiens ADP-ribosylation factor-like 4 (ARL4) 
 NM_006831.1 Homo sapiens CLP1, cleavage and polyadenylation 
factor I subunit, homolog (S. cerevisiae) (CLP1) 
 BC013437.1 Homo sapiens, Similar to MADS box transcription 
enhancer factor 2, polypeptide A (myocyte enhancer 
factor 2A), clone MGC:17198 IMAGE:3896491 
 NM_001673.2 Homo sapiens asparagine synthetase (ASNS), transcript 
variant 2 
 BC011885.1 Homo sapiens eukaryotic translation initiation factor 
2A, 65kDa 
 NM_016641.2 Homo sapiens membrane interacting protein of RGS16 
(MIR16) 
 NM_138461.1 Homo sapiens transmembrane 4 L six family member 
19 (TM4SF19) 
 NM_001983.1 Homo sapiens excision repair cross-complementing 
rodent repair deficiency, complementation group 1 
(includes overlapping antisense sequence) (ERCC1) 
 BC032862.1 Homo sapiens suppressor of cytokine signaling 5, 
mRNA (cDNA clone MGC:33746 IMAGE:5264754) 
 BC009485.1 Homo sapiens, clone MGC:16114 IMAGE:3623656 
 NM_002197.1 Homo sapiens aconitase 1, soluble (ACO1) 
 NM_080650.1 Homo sapiens similar to RIKEN cDNA 5730421E18 
gene (MGC14798) 
 NM_002916.1 Homo sapiens replication factor C (activator 1) 4, 
37kDa (RFC4) 
 NM_178523.2 Homo sapiens hypothetical protein MGC45556 
(MGC45556) 
 NM_001449.2 Homo sapiens four and a half LIM domains 1 (FHL1) 
 NM_021218.1 Homo sapiens chromosome 9 open reading frame 80 
(C9orf80) 
 BC020979.1 Homo sapiens ZW10 interactor, mRNA (cDNA clone 
MGC:9699 IMAGE:3848873) 
 BC005911.1 Homo sapiens sterol carrier protein 2 
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 BC019302.1 Homo sapiens LAS1-like (S. cerevisiae) 
 NM_005086.3 Homo sapiens sarcospan (Kras oncogene-associated 
gene) (SSPN) 
 BC015169.1 Homo sapiens ubiquitin-conjugating enzyme E2Z, 
mRNA (cDNA clone IMAGE:3898543) 
 BC011907.1 Homo sapiens PAK1 interacting protein 1, mRNA 
(cDNA clone MGC:13426 IMAGE:4251347) 
 BC029799.1 Homo sapiens DMRT-like family C1B 
 BC031300.1 Homo sapiens chromosome 21 open reading frame 2 
 BC020867.1 Homo sapiens solute carrier family 6 (neurotransmitter 
transporter, GABA), member 13 
 NM_024516.1 Homo sapiens hypothetical protein MGC4606 
(MGC4606) 
 NM_006333.1 Homo sapiens nuclear DNA-binding protein (C1D) 
 NM_005797.2 Homo sapiens myelin protein zero-like 2 (MPZL2), 
transcript variant 1 
 BC009738.1 Homo sapiens phenazine biosynthesis-like protein 
domain containing 
Chimera only BC065268.1 Homo sapiens protein-O-mannosyltransferase 1 
 BC004925.1 Homo sapiens G protein-coupled receptor, family C, 
group 5, member C 
 NM_006298.2 Homo sapiens zinc finger protein 192 (ZNF192) 
 NM_005736.2 Homo sapiens ARP1 actin-related protein 1 homolog 
A, centractin alpha (yeast) (ACTR1A) 
 NM_007284.1 Homo sapiens PTK9L protein tyrosine kinase 9-like 
(A6-related protein) (PTK9L) 
 BC022407.1 Homo sapiens SH2 domain containing 1B 
 NM_145313.1 Homo sapiens RasGEF domain family, member 1A 
(RASGEF1A) 
 BC002906.2 Homo sapiens uridine-cytidine kinase 2 
 NM_006460.1 Homo sapiens HMBA-inducible (HIS1) 
M1, E27 and 
Chimera 
NM_007284.1 Homo sapiens PTK9L protein tyrosine kinase 9-like 
(A6-related protein) (PTK9L) 
 
 
 
Is the N-terminus of hPRMT1-V1 involved in the formation  
of higher order oligomers in PRMTs? 
 The functional unit of PRMTs is the dimer.  It has been shown that dimer formation is 
important for the methyltransferase activity of PRMTs [13].  However, PRMTs have been shown 
to exist as higher order oligomers in solution, not dimers [13].  To test if truncating the NT of 
hPRMT1-V1 will influence the formation of these higher order oligomers in solution, gel 
filtration analysis of both the full length hPRMT1-V1-M1 and hPRMT1-V1-M11 truncated at 
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residue 10 was done.  It was observed that both hPRMT1-V1-M1 and hPRMT1-V1-M11 still 
existed as higher order oligomers in solution at approximately 400 KDa and 350 KDa 
respectively.  To test if the binding of AdoHcy will affect the size of oligomers formed by 
hPRMT1-V1-M1 and –M11 in solution, we incubated AdoHcy with each PRMT construct for 
one hour before gel filtration analysis.  A slight but not so significant shift in oligomer size was 
observed with both hPRMT1-V1 constructs (fig. 5-8).  Truncating the NT of hPRMT1-V1 did not 
hinder the formation of higher order oligomers in solution. 
 
 
 
 
Figure 5-8. Molecular weights of untagged PRMT1 constructs determined by gel filtration.  
15μM of untagged PRMT protein in 50mM phosphate buffer, pH 7.5 was loaded on to a gel 
filtration column (Phenomenex). Untagged PRMT constructs incubated with S-
adenosylhomocysteine (SAH) were also analyzed but no significant shift in peaks was observed.  
Untagged PRMT constructs form higher-order oligomers as shown by gel filtration 
chromatography.  
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Discussion 
 
 
Composition of the PRMT assay reaction 
 
PRMTs are known to exist as higher order oligomers in solution; however it is not known 
how oligomerization affects their activity.  It is possible that adding NP-40 (a detergent) to the 
PRMT assay mixture resulted in the disruption of not only these oligomers but also some of  
the PRMT-protein substrate interactions.  This will lead to a decrease in the number of substrate 
arginines methylated, explaining the decreased activity observed in the presence of NP-40.  
Although many proteins may be protected from oxidative damage by the addition of reducing 
agents, we observed that methylation activity decreased in the presence of DTT and conclude that 
this reagent should be omitted from PRMT1 reactions.   
The serum albumin protein, BSA is widely used in biochemical applications, including 
DNA digestion where it is used to stabilize some enzymes and prevent enzyme adhesion to 
reaction tubes.  It is therefore not very surprising that the presence of BSA in the PRMT assay 
mixture resulted in a significant increase in reaction rate.  We conclude that BSA should be added 
to PRMT reactions to stabilize the enzyme.  It is worth noting that BSA has not been reported to 
be methylated by any of the PRMTs.   
Our observations thus suggest that the reaction composition that will yield a high activity 
for hPRMT1-V1-M1 is: low nM hPRMT1-V1-M1, protein substrate, 10 nM MTAN, 1.0 μM 
AdoMet, 0.06 µCi/µL 3H-AdoMet, 100 mM Hepes buffer pH 8.0, 10% Glycerol, and 0.38 μM 
BSA.  This is the reagent composition used in all subsequent PRMT assays with protein 
substrates. 
 
The NT of hPRMT1-V1 influences enzymatic activity  
Several studies suggest that the NT of PRMTs is involved in enzymatic activity; deleting 
the NT of both PRMT3 and yeast arginine methyltransferase, Hmt1 resulted in a decrease in 
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enzymatic activity [10-12], and more recently, an increase in enzyme activity was observed 
when the NT of PRMT8 was removed [21] (Fig. 5-6).  In this study, we investigated the effect of 
the NT of hPRMT1-V1 on enzymatic activity with both peptide and protein substrates.  
Truncation studies showed that truncating the NT up to residue E27 did not affect enzyme activity 
with peptide substrate.  However, differences in enzyme activity towards protein substrates were 
observed when the NT of hPRMT1-V1 was truncated. 
Truncating the NT of PRMT1 should not affect activity with peptide substrates given that 
previous studies suggest that the NT does not interact with short substrate peptides nor does it take 
part in placing the substrate arginine in the active site [13].  hPRMT1-V1-M1, -M11 and -E27 
show similar activity with the peptide substrate thus supporting the above proposal.  However, 
hPRMT1-V1-S31 demonstrated extremely low activity (kcat, fig. 5-9).  In considering the location 
of Ser31 in the context of the crustal structure, it is possible that the NT was cut too close to the 
core (just one amino acid from the start of the X helix).  The NT of PRMTs has been reported to 
assist in the constraint of bound AdoHcy [13].  Truncating the NT up to amino acid 27 did not 
affect enzyme activity with peptide showing that AdoMet binding was not affected.  Conversely, 
truncating at S31 probably did not leave a long enough NT sequence to help in constraining 
AdoMet, resulting in the low activity of hPRMT1-V1-S31.   
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Figure 5-9.  Summary of NT sequences and kinetic parameters of hPRMT1-V1 constructs with 
peptide and protein substrates.   The PRMT6 NT sequence which is attached to hPRMT1-V1-E27 
core is shown in grey and the linker residues are shown in a lighter grey (-LE-).  Each column of 
kinetic parameters in the table corresponds to a hPRMT1-V1 construct obtained with either a 
peptide or protein substrate as indicated.   The last row in the table shows the number of proteins 
each construct interacted with in the protein array screen described earlier. 
 
 
The higher methyltranseferase activity consistently demonstrated by hPRMT1-V1-M11 
both on purified recombinant (kcat, fig. 5-9) and endogenous proteins (fig. 5-7) is possibly due to 
the absence of the first 10 amino acid residues at the NT.  It is possible that this 10 amino acid 
piece at the tip of the NT is involved in regulating the activity of hPRMT1-V1 in vivo.    Most 
PRMT substrates have multiple arginines which make them positively charged.  The substrate 
binding grooves of PRMT1 have been shown to be highly negatively charged due to a high 
incidence of acidic residues, this facilitates good interaction with the substrates.  The first 10 
amino acid piece of the NT mostly contains hydrophobic residues (70%), it only has 1 acidic 
residue (10%), and its polar residues make up the remaining 20% of its composition.  Due to its 
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overwhelming hydrophobicity, it is very unlikely that this 10 amino acid piece will interact 
with or bind positively charged regions of proteins.  The 21 amino acid piece next to the first 10 
amino acids on the NT is composed of 24% acidic residues, 5% positively charged residues, 24% 
hydrophobic residues and 47% polar residues.  Even though this 21 amino acid piece has an equal 
amount of both acidic and hydrophobic residues, it has a considerable amount of acidic residues 
for a small piece of protein and also a considerable amount of polar residues.  Also, the 
hydrophobic residues present in this 21 amino acid piece are scattered throughout this portion of 
the protein and not concentrated in one place as with the 10 amino acid piece.  It is therefore 
possible that this 21 amino acid piece will interact with positively charged regions of proteins.  
Consequently, I propose that this 21 amino acid piece at the NT binds to a positively charged 
region on the protein substrate positioning it in the right orientation for binding and catalysis to 
occur.  On the other hand, the first 10 amino acid piece binds to a hydrophobic patch on the 
substrate protein resulting in an orientation of the protein that is not very favorable for binding 
and catalysis at the enzyme active site.  Therefore on the full length protein (hPRMT1-V1-M1) 
which has both peptide portions, there is a 50% chance of either one binding first to the protein 
substrate.  If the 21 amino acid piece binds first, there will be methylation of the protein substrate.  
But if the 10 amino acid piece binds first, no catalysis will occur and the protein will have to 
dissociate and rebind in the right orientation for catalysis to occur (fig. 5-10).  This will result in a 
decrease in enzyme activity as observed with hPRMT1-V1-M1, since binding will only result in 
catalysis part of the time.  However, with hPRMT1-V1-M11 where the 10 amino acid piece is 
lacking, the protein can only bind to the 21 amino acid piece, implying that every binding event 
will result in catalysis consequently increased activity observed (fig. 5-10).  When the first 16 of 
the 21 amino acids at the NT of hPRMT1-V1-M11 are truncated (hPRMT1-V1-E27), most of the 
acidic residues are removed as such correct binding and orientation of the protein at the active site 
is no longer facilitated by the binding of the N-terminal 21 amino acid residue piece.  Protein 
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substrates will therefore possibly take longer to bind in the right orientation at the active site, 
resulting in an observed lower enzyme activity.  This 21 amino acid piece can also possibly be 
involved in stabilizing the protein substrate in the active site; as such deleting most of it will leave 
a small piece that can no longer carry out this function fully, resulting in fewer substrate arginines 
being methylated (fig. 5-10).  It is not well understood why the chimera which is similar to 
hPRMT1-V1-E27 but for the additional PRMT6 NT showed lower enzymatic activity towards 
both purified and endogenous proteins.  These results strongly suggest that the NT of hPRMT1-
V1 influences methyltranseferase activity.  This is similar to what was observed with PRMT8 
whereby, cutting off the NT resulted in an increase in activity [21]. 
 
 
Figure 5-10. Model for the N-terminal regulation of hPRMT1-V1 enzyme activity.  A less active 
full-length hPRMT1-M1 contains an additional predominantly hydrophobic 10 amino acid piece 
at the tip of the NT (denoted by, oooo).  Increase activity occurs when the 10 amino acid piece is 
removed in hPRMT1-V1-M11.  In vivo, we suggest that the 10 amino acid piece regulates the 
activity of hPRMT1-V1 by some times binding to a hydrophobic region of the protein substrate 
(denoted by, oooo) leading to an orientation of the substrate which may bind the PRMT in a way 
that does not allow for catalysis (right).  On the other hand, if a positively charged region of the 
protein substrate (denoted by, +++++) binds to the negatively charged 21 amino acid piece 
(denoted by, -----) which is next to the 10 amino acid piece, this will result in an orientation of the 
protein that will effectively bind the PRMT favoring catalysis (left).  Therefore hPRMT1-V1-
M11 is more active because every binding event results in catalysis, meanwhile with hPRMT1-
V1-M1 only some of the binding events result in catalysis consequently lowers activity. 
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The effect of truncating the NT of hPRMT1-V1  
on substrate specificity is substrate dependent  
Previous studies showed that deleting the NT of PRMT3 (amino acid residues 1 to183) 
resulted in the alteration of its substrate specificity [10, 11].  Also, a study of seven spliced 
variants of C-terminally Histidine tagged hPRMT1 which have different N-terminal lengths and 
sequences, suggested that a difference in substrate specificity exists amongst these variants [9].  
Unlike PRMT3, truncating the NT of hPRMT1-V1 did not alter its substrate specificity towards 
hnRNP K recombinant protein tested (kcat/Km, fig. 5-9).  However, removal of the first 26 amino 
acids of hPRMT1-V1 resulted in an order of magnitude increase in kcat/Km for Histone H4 
protein (kcat/Km), fig. 5-9). 
When endogenous proteins from ES-/- cells were methylated for a maximum of 30 
minutes, some proteins were not visible with hPRMT1-V1-M1 and the chimera, but were very 
clear with both hPRMT1-V1-M11 and –E27.  Also, hPRMT1-V1-M1 showed some difficulty in 
methylating lower molecular weight proteins in the nuclear extract, which both hPRMT1-V1-
M11 and –E27 had no trouble methylating in 30 minutes.  hPRMT1-V1 construct is slightly more 
restricted, additional experiments where longer incubations are tested will have to be performed.  
The difference we see might also be due to the difference in enzyme activity between the 
constructs; since hPRMT1-V1-M1 has the lowest activity, it might actually be taking more time 
to methylate what hPRMT1-V-M11 and –E27 methylate in a shorter time.  We can therefore say 
that given our current experimental conditions, we did not observe significant differences in 
substrate specificity amongst the hPRMT1-V1 truncation constructs and bulk protein substrates. 
 
The NT of hPRMT1-V1 influences protein-protein  
interactions 
When solving the crystal structure of PRMT1, no electron density was obtained for the 
NT, indicating that it is disordered.  The large scale screen for protein-protein interactions 
between the purified hPRMT1-V1 constructs and immobilized proteins described in the results 
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section showed that the NT can influence protein-protein interactions, as certain proteins only 
interacted with specific constructs and others interacted with two or more hPRMT1-V1 
constructs.  A similar trend to that observed with the enzyme activity of each hPRMT1-V1 
construct toward the two protein substrates tested (kcat, fig. 5-9), was observed with the number of 
proteins each construct interacted with.  hPRMT1-V1-M1, which is the full length construct, 
interacted with the fewest number of proteins.  The 10 amino acid piece present at the NT possibly 
gives hPRMT1-V1-M1 more specificity as to which proteins to interact with.  hPRMT1-V1-M11 
which lacks the first 10 amino acids at the NT interacts with almost four times more proteins than 
does hPRMT1-V1-M1.  Strangely enough, truncating 16 more amino acids from the NT of 
hPRMT1-V1-M11 resulted in hPRMT1-V1-E27 interacting with almost 2-fold fewer proteins.  
This is a possible indication that this 16 amino acid fragment (residues 11 to 26) increases the 
ability of hPRMT1-V1 to interact with many proteins non-specifically.  Suggesting that addition 
of the 10 amino acid piece (residues 1 to 10) at the NT of this 16 amino acid piece (as is the case 
with hPRMT1-V1-M1) serves to regulate it, increasing its specificity in protein-protein 
interactions, hence reducing the number of proteins it can interact with.  This is most likely not 
the case with the PRMT6 NT as its addition to the core of hPRMT1-V1 considerably increased the 
number of proteins the PRMT6 NT: hPRMT1-V1-E27 chimera interacted with by a little over two 
fold.  It is therefore reasonable to say that the first 10 amino acids at the NT of hPRMT1-V1 serve 
as a regulatory piece, regulating the interaction of hPRMT1-V1 with certain proteins.  I propose 
that the first 10 amino acids at the NT of hPRMT1 may also function in regulating the protein-
protein interactions of hPRMT1 towards certain substrates in vivo. 
 
Truncating the NT of hPRMT1-V1 does not influence  
oligomer formation by hPRMT1-V1 
It has been previously observed that in solution PRMTs exist as higher order oligomers  
[13].  A study showed that the oligomerization of the yeast arginine methyltransferase, Hmt1 is 
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considerably hindered when its NT is deleted [12].  To test if the NT of hPRMT1-V1 is 
involved in oligomer formation, gel filtration analysis of solutions of hPRMT1-V1-M1 and 
hPRMT1-M11 were done.  The results obtained show that truncating the NT of hPRMT1-V1 did 
not affect the oligomerization of hPRMT1-V1.  This means that in the higher order oligomers of 
hPRMT1-V1, the PRMT dimers probably interact at sites other than the NT.  The NT therefore 
does not significantly contribute to the formation of higher order oligomers by hPRMT1-V1 in 
solution. 
 
Conclusion 
It has long been postulated that the NT of PRMTs is involved in enzyme activity, 
substrate specificity, and protein-protein interactions, but very little is known on how this 
happens.  In this chapter, using hPRMT1-V1 as a model, I show that the NT is involved in 
protein-protein interactions and also influences enzyme activity.  On the other hand, truncating 
the NT either did or did not influence substrate specificity based on what protein substrate was 
used.  Here I propose that the amino acid N-terminal sequence composition is what influences 
substrate specificity, not the length.   I also suggest that the first 10 amino acids at the NT of 
hPRMT1 may function in regulating both the enzymatic activity and protein-protein interactions 
of hPRMT1-V1 in vivo.  The N-terminus has previously been shown to function in regulating the 
activity of enzymes [10, 11, 21-23]. 
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CHAPTER 6 
 
COMPLETED PROJECTS, PROJECTS IN PROGRESS, AND INTERESTING 
OBSERVATIONS 
 
Project 1: Expression and Purification of C-terminal  
Histidine6-tagged PRMT1 Variants 
In order to study the role of the PRMT1 N-terminus we obtained six DNA vectors, each 
containing one of the first six human PRMT1 alternative splice variants from our collaborator 
Jocelyn Cote (University of Ottawa, Canada).  PRMT1 variant 7 was not available.  These 
variants have a similar core domain but differ at their N-termini.  They also have a C-terminal 
Histidine6 (His6) – tag.  To use these variants to determine if the difference in their N-terminal 
sequence affects their substrate preference, they had to be expressed and purified.  All seven 
splice variants were expressed and purified similarly.  DNA vectors were transformed into BL21 
E. coli cells and single colonies obtained.  Single colonies were used to inoculate start up 
cultures, which were used to inoculate 2.5 L of culture media.  Cells were grown to an OD280600 
of 600 0.6 at 37ºC and then induced with 1mM IPTG for four hours.  Cells were harvested by 
centrifuging at 10,000 RPM for 20 minutes.  Cells were resuspended in 5 ml loading buffer (50 
mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, 20 mM 2-mercaptoethanol), and sonicated on 
ice.  Cell debris was pelleted by centrifugation.  The supernatant was incubated with 1.25 ml of 
50 % slurry of Ni-NTA resin beads, overnight at 4ºC.  The resin with bound protein was first 
washed with 15 ml wash buffer (50 mM Na2HPO4, 10 mM imidazole, 1M NaCl), and then with 
22.5 ml wash buffer (50 mM Na2HPO4, 10 mM imidazole, 300 mM NaCl).  Proteins were eluted 
in 1ml fractions to a total of 5 ml of elution buffer (50 mM Na2HPO4, 300 mM NaCl, 250 mM 
imidazole).  Fractions containing clean protein were pooled, concentrated and the buffer 
exchanged to a heparin column binding buffer (10 mM sodium phosphate, pH 7.0).   The 
concentrated proteins were loaded onto a heparin column.  The column was washed with 12.5 ml 
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binding buffer, and the bound proteins were eluted by a salt gradient, with the salt 
concentration increased in a stepwise manner from 0.2 M to 1.5 M NaCl (elution buffer : 10 mM 
sodium phosphate, pH 7.0, 1.5 M NaCl).  Fractions were analyzed by SDS-PAGE and those 
containing clean proteins were pulled, concentrated and buffer exchanged to storage buffer (50 
mM sodium phosphate, pH 7.0) (Fig. 6-1).  Protein was frozen and stored at -80ºC.  The heparin 
column is the column that did the best job of cleaning up the proteins, as both cobalt resin and 
MonoQ columns did very little to purify the protein.  In conclusion, a combination of Ni-NTA 
resin followed by a heparin column is the best way to purify the C-terminal His6-tagged human 
PRMT1 variants. 
 
 
 
 
Figure 6-1. Coomassie stained gel of purified PRMT1 variants 1-6.  Proteins were purified using 
Ni-NTA resin, followed by a heparin column.  Arrows indicate each purified PRMT variant.   
 
 
The purified proteins were then used in a continuous spectrophotometric assay previously 
described in chapters 3 and 4, to determine their activity with the peptide substrate R3 
(acetylGGRGGFGGRGGFGGRGGFG), which is derived from fibrillarin.  The N-terminus is not 
expected to affect PRMT1 activity with a peptide substrate, making this assay a good way to 
check the activities of these variants.  The assay utilized 200 μM R3 peptide, 4 μM hPRMT1,  
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10 nM AdoHcy/MTA nucleosidase, 0.02 μM Adenine Deaminase, 10 nM MnSO4, 250 μM  
S-Adenosylmethionine, and 50 mM sodium phosphate buffer pH 7.1.  R3 peptide was used to 
initiate the reactions and a decrease in absorbance at 265 nm was measured.  When the assay was 
performed, the enzymes were found not to be very active as the rate of the variants with 200 μM 
R3 peptide was barely over that of the control (Fig. 6-2).  Also, there was much scatter observed 
in the obtained data points.  This low activity is probably because the His6-tag is attached at the 
C-terminus of the PRMT1 splice variants.  In the solved PRMT1 structure, the C-terminus is seen 
to be very close to the active site.  Therefore attaching a His6-tag to the C-terminus might 
interfere with the substrate binding or activity of the active site.  These results suggest that  
C-terminal tags should be avoided in PRMT isoforms that have a C-terminus near the active site. 
 
 
 
 
Figure 6-2.  The continuous assay monitors the methylation of the R3 peptide by the PRMT1 
variants.  The graphs show a decrease in absorbance at 265 nM over time.  The control reaction is 
shown in black, while the reaction with 200 μM R3 is in blue.  The rates for all six variants are 
shown; PRMT1 variant 1 (A), PRMT1 variant 2 (B), PRMT1 variant 3 (C), PRMT1 variant 4 
(D), PRMT1 variant 5 (E), and PRMT1 variant 6 (F). 
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Project 2: Comparison of Methyl Arginine Proteome  
from Cells Treated with Particulate Matter vs. Cells  
Treated with Asbestos 
 
This project is being done in collaboration with David W. Kamp, M.D. at Northwestern 
University Feinberg School of Medicine.  The Kamp lab has previously reported that particulate 
matter (PM) induces p53-dependent apoptosis in primary human alveolar epithelial cells [1].  
Prior to this, the Aust lab showed that crocidolite asbestos causes apoptosis of A549 cells (human 
epithelial lung cells) [2].   Our lab has previously observed a difference in the methyl arginine 
proteome between control and A549 cells treated with asbestos.  We therefore set out to 
determine if the methyl arginine proteome change observed in crocidolite asbestos treated A549 
cells, is also observed with particulate matter treated A549 cells and if this change is associated 
with apoptosis.  To test this hypothesis, six conditions were set up;   
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1. A549 Control 
2. A549- Crocidolite Asbestos 6 μg/cm2 (24 h) 
3. A549 - PM 6 μg/cm2 (24 h) 
4. A549-Bclxl overexpression 
5. A549-Bclxl overexpression - Crocidolie Asbestos 6 μg/cm2 
6. A549-Bclxl overexpression - PM 6 μg/cm2 (24 h). 
The Bclx1 protein inhibits apoptosis, therefore cells stably overexpressing the Bclx1 protein 
should not undergo apoptosis even when treated with asbestos or PM. We expected to see a 
change in the methyl arginine proteome when A549 cells are treated with asbestos and PM.  If 
apoptosis is required for this proteome change to take place, no change in methyl arginine 
proteome will be observed when Bclx1 overexpressing cells are treated with either asbestos or 
PM.  But if apoptosis is not required, then a change will be observed in both treatments. 
The A549 cells were lysed in phosphate buffered saline (PBS) and their concentrations 
determined using the DC protein assay from BioRad.  The concentration of the lysates was low 
and some were very low such that the same protein concentration could not be loaded for all of 
them. 
 Based on the western blot shown below (Fig. 6-3), there are six positions where we see 
potential differences, but no absolute conclusions can be made as of now.  This is mainly due to 
the fact that the actin blot shows differences in the protein amounts loaded.  The protein 
concentrations have to be re-determined and another western blot done before a conclusion can be 
reached.  
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Figure 6-3. Western blot of lysates obtained from A549 treated and untreated cells.  (A) The top 
panel shows the western blot using Asym24 which is an antibody against asymmetric 
dimethylarginines.  The amount of protein loaded is indicated for each lane.  * Indicate observed 
differences.  (B) This is an actin blot to determine if the same protein concentration was loaded 
for all lanes.  This western was done using an anti-actin primary antibody. 
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Project 3:  Is the N-terminus of hPRMT1-V1  
Involved in Protein-Protein Interactions with  
the PRMT1 Regulator hCAF1?  
 
 
Introduction 
 CCR4-associated factor1 (hCAF1), B-cell translocation gene 1 and -2 (BTG1 and -2) are 
the only proteins that have so far been shown to have the ability to regulate the activity of 
PRMT1 in cells [3-5].  hCAF1 regulates the activity of PRMT1 by complex formation, but what 
surfaces are involved in the interaction of these two proteins is unknown.  To test if the N-
terminus of hPRMT1-V1 is important for interaction with hCAF1 protein, we conducted 
pulldown experiments in an attempt to see if recombinant GST-hCAF1 would still interact with 
and pull down each truncated construct of hPRMT1-V1.   
 
Method 
Prewashed GST-resin (100 μL packed) was incubated with 410 μM (9.7 μg) GST-hCAF1 
for three hours at 4ºC with tumbling, to allow binding of protein to resin.  The resin was then 
washed five times with 1000 μL 1xPBS each time to remove unbound hCAF1 protein.  Resin was 
resuspended in 400 μL 1xPBS and protease inhibitors added.  100 μL of protein bound-resin 
suspension was put into four separate tubes and 154 μM of each hPRMT1-V1 construct added to 
individual tubes.  Mixtures were incubated for four hours at 4ºC with tumbling to allow binding 
of the hPRMT1-V1 construct to hCAF1.  The resin was washed 12 times with 500 μL 1xPBS 
each time to remove unbound hPRMT1-V1 protein constructs.  15 μL of 4x SDS sample buffer 
was added to each resin with bound protein and boiled for eight minutes.  Samples were resolved 
on 10 % SDS-PAGE gels and proteins transferred to PVDF membranes.  The westerns were first 
probed with a GST antibody to check for the presence of GST-hCAF1.  The membrane was then 
stripped and probed with an antibody against PRMT1 to find out which of the different hPRMT1-
V1 proteins were pulled down by hCAF1. 
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Results, Discussion, and Conclusion 
All the truncation constructs hPRMT1-V1-M1, -M11, -E27 and -S31 were pulled down 
by GST-hCAF1 (fig. 6-4).  hCAF1 interacts with PRMT1 both in vivo and in vitro regulating its 
activity in a substrate dependent manner.  Our results suggest that the NT of hPRMT1 is not 
critical in its interaction with hCAF1 as all the truncation constructs formed complexes with 
hCAF1.  However, a control experiment still needs to be done where a PRMT that is not known 
to interact with hCAF1 for instance, His-PRMT6, is incubated with hCAF1 under similar 
conditions and the outcome noted.  If hCAF1 pulls down His-PRMT6, then maybe the current 
conditions are very favorable for protein-protein interactions, hence the entire pull down 
experiment should be repeated under more stringent conditions.  For instance the new conditions 
can mimic the conditions used in the Protoarray protein-protein interaction screen done in chapter 
5 (outlined in the manufacturer’s manual). 
 
 
 
 
Figure 6-4.  The hPRMT1-V1 NT is not critical for protein-protein interaction with hCAF1.  
Equal amounts of the hPRMT1-V1 constructs were each incubated with the same amount of 
GST-hCAF1 pre-bound to GST-beads for 4 hours.  After extensive washing of resin, 4X SDS 
sample buffer was used to elute the bound proteins by boiling for 8 mins.  Eluted proteins were 
resolved on SDS-PAGE and transferred to PVDF membranes.  A) Westerns were probed with 
GST antibody (Santa Cruz Biotechnology) to check for the presence of hCAF1.  B) Membranes 
from (A) were stripped and reprobed with antibodies against PRMT1 (Upstate) to determine the 
presence of the hPRMT1-V1 constructs pulled down by GST-hCAF1. 
A) 
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Observation 1: When the Human PRMT1  
Variant 1 E27 Construct is used in an Assay  
with Protein Substrate, the Enzyme could not  
be Saturated at the Substrate Concentration Used 
 
  When using the ZipTip assay to look at the steady state kinetics of the PRMT1 variant 1 
E27 (hPRMT1-V1-E27) construct with the protein substrate GST-MRE11 B, 790 nM of this 
enzyme was mistakenly used instead of 70 nM.  Analysis of the data from this experiment 
revealed that this PRMT construct at this high concentration did not show saturation (Fig. 6-5).  
However, when this experiment was repeated with enzyme at low concentration (70 nM), the data 
obtained could not be fitted into any particular kind of curve (Fig. 6-6A).  Repetition of some of 
the data points which seemed to be questionable still resulted in a similar pattern.   
 To test if this was just a characteristic of hPRMT1-V1-E27 with this substrate or if the 
other constructs will demonstrate the same pattern, we did steady state kinetics of hPRMT1-V1-
M1 with the same protein (GST-MRE11 B) at an enzyme concentration of 70 nM.  Unlike 
hPRMT1-V1-E27, hPRMT1-V1-M1 showed a rapid linear increase in rate with increasing 
protein substrate, followed by saturation (Fig. 6-6B). 
  This suggests that the phenomenon observed with hPRMT1-V1-E27 and GST-MRE11 
B, is not due to the substrate only, since the substrate shows normal steady state kinetics with 
B) 
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hPRMT1-V1-M1.  No other protein substrate tested with hPRMT1-V1-E27 produced similar 
results.  This is possibly a situation where hPRMT1-V1-E27 reacts with this particular substrate 
differently than hPRMT1-V1-M1.  This observation needs to be further explored with different 
enzyme concentrations, different enzyme batches and different enzyme substrates. 
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Figure 6-5.  A plot of the rate of methylation of GST-MRE11 B per min against the 
concentration of GST-MRE11 B shows that PRMT1 variant 1 E27 could not be saturated at a 
concentration of 790 nM.This ZipTip assay contained 1.88 μCi 3H-AdoMet, 100 mM Hepes 
buffer at pH 8.0, 0.38 μM BSA, 10 % Glycerol, 10 nM MTAN and GST-MRE11 B at varying 
concentrations.  The reactions were initiated with 790 nM PRMT1 variant 1 E27, and 10 μl 
timepoints taken out and processed as previously described in chapter 4. 
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Figure 6-6. Kinetic analysis of the methylation of GST-MRE11 B by hPRMT1-V1-E27 and 
hPRMT1-V1-M1.  (A) Rate of methylation (nMCH3/min) versus GST-MRE11 B concentration 
catalyzed by hPRMT1-V1-E27.  (B) Steady-state analysis of the methylation of GST-MRE11 B 
by hPRMT1-V1-M1.  The assays were performed by ZipTip as previously described in chapter 4.   
70 nM PRMT was utilized in these assays.  
A 
B 
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Observation 2:  When in vitro Methylation Assays  
are done in HEPES Buffer versus Sodium Phosphate  
Buffer; Differences in PRMT Activity are observed. 
 
Histidine6-tagged eukaryotic translation initiation factor 4A, isoform 1 (His-eIF4a1) 
protein has previously been shown to be a substrate of PRMT1 [6].  However, several attempts at 
methylating purified recombinant (His-eIF4a1) protein with hPRMT1-M1, -M11, or E27, were 
unsuccessful.  The reaction mixture consisted of 1.88 μCi 3H-AdoMet, 100 mM Hepes buffer at 
pH 8.0, 0.38 μM BSA, 10% Glycerol, 10 nM MTAN, 10 μM His-eIF4a1 and 100 nM  of either 
hPRMT1-M1, -M11, or E27, which were used to initiate each reaction.  Since His-eIF4a1 has 
been shown to be methylated before in sodium phosphate buffer, we decided to repeat the 
methylation reaction but this time use sodium phosphate buffer (100 mM, pH8.0) instead of 
Hepes buffer.  Interestingly, methylation of His-eIF4a1 was observed (Fig. 6-7) this time.  These 
reactions were done at 37 ºC for 1 hour.  Each reaction was halted in 4X sample buffer and boiled 
for 5 minutes.  They were then resolved on SDS-PAGE and the proteins transferred to a PVDF 
membrane.  The membrane was dried and sprayed with En3Hance from Perkin Elmer according 
to the manufacturer’s directions and then incubated with film for 5 days.  The methylated proteins 
were then viewed by fluorography. 
This observation was further investigated by methylating endogenous protein obtained 
from PRMT1-/- ES cells with PRMT6 NT: hPRMT1-V1-E27 core chimera.  We decided to 
reinvestigate the activity of the chimera to see if it was more active in Hepes buffer.  The reaction 
mixtures were similar except for having either Hepes or sodium phosphate buffer, they consisted 
of ; 1.88 μCi [3H]-AdoMet, 100 mM Hepes  or sodium phosphate buffer at pH 8.0, 0.38 μM BSA, 
10% Glycerol, 10 nM MTAN, 15 μg total endogenous protein and 280 nM  
PRMT6 NT: hPRMT1-V1-E27 core chimera.  The reactions were treated the same way as the 
His-eIF4a1 methylation assay described above.  The resulting fluorograph shows that the chimera 
is not as active in Hepes buffer as when in sodium phosphate buffer (Fig. 6-8).  Most surprising is 
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that some proteins were only methylated in Hepes while others were only methylated in 
phosphate buffer. 
 
 
 
 
 
Figure 6-7.  Effect of buffer composition on hPRMT1 activity.  Figure shows methylation of His-
eIF4a1 in sodium phosphate buffer but not in Hepes buffer.  Arrow shows methylated His-
eIF4a1. 
 
 
It is not understood why the methyltransferase activity of PRMTs differ in either Hepes 
buffer or sodium phosphate buffer.  This effect of buffers on the activity of PRMTs has to be 
further investigated as this will greatly impact the PRMT field since certain labs exclusively use 
sodium phosphate buffer and others Hepes buffer in their study of PRMTs in vitro.  Maybe some 
of the proteins that PRMTs have been reported as showing less preference for in sodium 
phosphate buffer will be more favored in Hepes buffer and vice versa.  Therefore the PRMT field 
has to come to an agreement as to which buffer should be used for in vitro assays in the study of 
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PRMTs.  Understanding how different buffer compositions selectively affect specific protein 
methylations may also reveal novel ways in which the PRMTs are regulated in vivo. 
 
 
 
 
Figure 6-8.  Activity of PRMT6 NT: hPRMT1-V1-E27 core chimera towards endogenous 
proteins differs in Hepes buffer and sodium phosphate buffer.  Stars (   ) show proteins that the 
chimera is less active towards in sodium phosphate buffer and the arrow shows the protein that 
the chimera is more active towards in sodium phosphate buffer. 
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CHAPTER 7 
SUMMARY AND FUTURE WORK 
 
 
Summary 
 
 The activity of most eukaryotic proteins is modulated by post-translational modifications 
(PTMs) that increase the structural and functional diversity of the proteome.  PTMs like 
phosphorylation and acetylation of proteins have been widely studied and their roles in the 
regulation of cellular processes such as signal transduction and gene expression are well 
understood.  Recently, the importance of another kind of PTM, known as methylation has begun 
to be recognized.  Protein methylation can occur on amino acid residues such as lysine, histidine, 
asparagine, glutamine, proline, or arginine, some of them more frequent than others.  Arginine 
methylation is a common methylation that is involved in numerous cellular processes and is 
catalyzed by a family of enzymes known as protein arginine methyltransferases (PRMTs).  
Although PRMTs have been around for a while, a lot of pertinent questions still remain in the 
field; how is substrate specificity achieved amongst the PRMTs; how is PRMT activity regulated 
by posttranslational modifications such as phosphorylation, acetylation, ubiquitination and trans- 
or automethylation; are there really enzymes that demethylate arginine residues; other than Tudor 
domains, are there additional modules that bind methylarginine? 
 In other to contribute to the advancement of the PRMT field, I decided to investigate 
claims that the PRMT N-terminus (NT) influences enzymatic activity, protein-protein interaction 
and substrate specificity.  In this study, I used human PRMT1 variant 1 (hPRMT1-V1) as a 
model.  hPRMT1 is the PRMT of choice in this study because it is the major PRMT in the cell 
methylating over 85% of all protein arginine residues and has also been implicated in a number of 
disease conditions such as cancer.  hPRMT1 also has the highest number of variants as a result of 
alternative splicing (variants 1-7).  In other to do this study, we first made untagged hPRMT1-V1 
truncation constructs and a protein chimera consisting of a PRMT6 NT and a hPRMT1 core 
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starting from residue 27.  These constructs were then used in the development of a fast and 
efficient assay for the quantitative analysis of s-adenosyl methionine dependent enzymes.  
Finally, we used this assay to analyze the effect the NT of hPRMT1 on enzymatic activity, 
protein-protein interaction and substrate specificity. 
 The PRMT field has greatly advanced from when PRMTs were first discovered.  Much 
of what is known about PRMTs was attained by studying the properties of recombinant PRMTs.  
However, these recombinant proteins are usually expressed as tagged fusion proteins, and it has 
been shown that the nature of the tag used at the NT of PRMTs differentially affects methylation 
of certain protein substrates.  To solve this problem, we developed a method of obtaining purified 
untagged recombinant PRMTs, which uses osmotic shock to lyse the bacteria cells harboring the 
expressed protein.  In this method, we start by purifying a recombinant protein bearing a tobacco 
etch virus (TEV) cleavable affinity tag.  TEV cleavage site is then cleaved using TEV protease 
leaving behind only a single glycine residue.  Passage over a second affinity column achieves 
separation of the untagged PRMT and the TEV cleavage site linked to the affinity tag.  Untagged 
PRMTs obtained by this method are active and can be used in a variety of studies in which the 
properties of PRMTs are being investigated without worrying about the effect of a tag.  
Importantly, this method can be used in the purification of other problematic TEV fusion 
constructs that show possibly disordered N or C termini. 
 For a longtime, one major hindrance to the advancement of the PRMT field has been the 
lack of fast and efficient ways to quantitatively measure PRMT activity with protein substrates, 
the existing techniques take anywhere from 10 weeks to 4 months to obtain a single data point.  
Meanwhile several fast techniques exist for measuring PRMT activity with peptides which do not 
work well if at all with proteins.  However, in order to reflect what might be happening in vivo, 
there is need to move from studying the properties of PRMTs with peptide substrates to protein 
substrates.  As a major highlight of my research, we developed a fast and efficient assay for the 
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quantitative measurement of s-adenosyl-L-methionine (AdoMet)-dependent 
methyltransferase activity with protein substrates.  This method employs the capability of a 
reverse-phase resin packed at the end of a pipette tip to bind radiolabeled protein products and not 
unreacted [3H]-AdoMet as such quickly separating the two (Fig. 7-1).  The radiolabeled protein 
products bound to the resin are then eluted into scintillation cocktail and counted in a liquid 
scintillation counter.  This assay comes with several advantages over existing methods; (i) it 
decreases the analysis time, (ii) it is very sensitive allowing for the determination of  initial rate 
data, (iii) the volume of radioactive waste is reduced by more than 3000-fold over existing 
protocols, (iv) it can be used to study the inhibitory effect of s-adenosylhomocysteine (AdoHcy), 
(v) it does not use coupling enzymes as such false-positive hits are reduced, thus making this 
assay highly suitable for use in screening modulators of protein methyltransferase activity, (vi) it 
can be optimized for high-throughput screens, and (vii) finally, this assay will work for other 
AdoMet-dependent protein methyltransferases including lysine methyltransferases, and carboxyl 
methyltransferases. 
We then set out to use this assay together with protein arrays, the continuous 
spectrophotometric assay and other standard protocols to analyze the effect of the NT of 
hPRMT1-V1 on enzymatic activity, protein-protein interaction, and substrate specificity.  This 
study confirmed reports that the NT influences enzymatic activity with protein substrates and 
protein-protein interactions.  It also identified a piece of the NT which consists of the first 10 
amino acid residues that might be regulating the activity and what proteins hPRMT1 interacts 
with in vivo.  This is because truncation of this piece results in an increase in enzyme activity and 
in the number of proteins that the enzyme interacts with.  This observation is similar to what has 
been reported in PRMT8 where cleavage of the NT resulted in an increase in enzyme activity 
(Chapter 5).  However, truncating the NT of hPRMT1-V1 at Methionine 11 did not affect 
substrate specificity towards the recombinant proteins tested nor the endogenous proteins from 
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mouse PRMT1-/- ES (embryonic stem) cells.  Nevertheless, truncating at Glutamate 27 
influenced substrate specificity towards Histone H4 protein.  I propose that the difference in 
substrate specificity suggested between hPRMT1 variants which have the same core but different 
N-termini, is due to the difference in their NT sequences, not their lengths, since the absence of 
the hPRMT1-V1 did not significantly influence substrate specificity. 
 
 
 
 
 
Figure 7-1.  Summary of how the new fast and efficient assay for the measurement of S-
adenosylmethionine-dependent protein methylation works.  The main thing that makes this 
method different from others is its ability to separate unreacted [3H]-AdoMet (*AdoMet) from 
radiolabeled proteins ( ) quickly and efficiently.  Unlabeled proteins are shown in blue ( ). 
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Future Work 
 More work still has to be done in order to confirm the model proposed above and also to 
further this field. 
Firstly, I suggest the utilization of site directed mutagenesis to mutate some of the 
residues in the first 10 amino acids of the NT.  This will make it possible to tell which residues at 
the NT are important for regulating the activity and protein-protein interactions of hPRMT1.  It 
will also be advantageous to mutate some of the residues between residues 11 and 27, to find out 
which ones played an important role in the increase enzyme activity observed when the first 10 
amino acids were truncated. 
Secondly, I suggest doing a peptide competition assay using two peptides, one that 
corresponds to the first 10 amino acids of the hPRMT1 NT and another which corresponds to the 
first 27 amino acids of the NT.  Each peptide will be pre-incubated with the protein substrate in 
separate reactions for at least 30 minutes before the assay is initiated with the hPRMT1 enzyme.  
The assay will then be carried out in a similar manner as described in chapter 4.  Analysis of these 
results will illustrate if either of the N-terminal peptides was able to bind to a certain portion of 
the protein thus hindering or delaying the binding of the added hPRMT1 enzyme to the protein.  
This will be observed as a decrease in enzyme activity when compared to a parallel assay reaction 
done in the absence of either N-terminal peptides. 
Also, to confirm that there are no differences in the abilities of each of the hPRMT1-V1 
constructs to bind AdoMet, I suggest that it is important for the Kd (dissociation constant) of each 
construct be obtained.  This can be done using intrinsic fluorescence which is a technique that our 
lab is familiar with.  This technique is currently in active use in our lab and is not very time 
consuming compared to other methods that are usually used for this purpose. 
Using stopped-flow fluorescence the movement of the NT can be monitored before and 
during catalysis.  This has been done with DNA methyltransferase where the movement of a loop 
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was observed using this method.  This will require the use of a stopped-flow reaction 
analyzer.  Norbert Reich of the University of California, Santa Barbara, has this instrument, and 
this project can be done in collaboration with him.  He has previously given a seminar at our 
department and is familiar with our work.  To do this, one or two amino acid residues at the NT 
will have to be mutated to tryptophan (W); this can be done using the QuikChange kit from 
Stratagene.  Already purified protein substrates such as hnRNP k and Histone H4 can be used. 
Also proteins which interact with h PRMT1-V1 but which are not substrates can be used, this will 
allow observation of what the NT does without a favorable spot to bind to.  There are five other 
tryptophans in hPRMT1-V1, to make sure that only the movements of the tryptophans at the NT 
are being observed, wild type hPRMT1-V1 will be used as a control and the results from this will 
be subtracted as background from the reactions with the mutants.  In this reaction, the enzyme is 
first preincubated with the protein substrate and mixed in the stopped-flow apparatus with 
cofactor (AdoMet or AdoHcy).  Using AdoHcy allows one to examine binding, while using 
AdoMet allows one to view catalysis.  This way, the change in conformation of the NT can be 
observed during binding and catalysis.  The results gathered from this experiment will be 
differences in observed fluorescence intensity which indicate shifts in the amounts of the various 
NT tail conformers.  No observable fluorescence change will suggest that there has been no 
significant change in amount, meaning no binding. 
hPRMT1-V1 shuttles between the nucleus and the cytoplasm although it is mainly 
localized in the nucleus, but it neither has a nuclear localization signal nor a nuclear export signal.  
It is not known what allows it to localize to either the nucleus or cytoplasm.   Since truncation 
constructs of hPRMT1-V1 and a chimera consisting of the NT of PRMT6 and hPRMT1-V1 core 
have already been made, it will be interesting to put these constructs into a GFP vector and 
transfect HEK293 cells.  Confocal microscopy can then be used to see what part of the cell each 
construct will localize to.  If the NT is important for either nuclear localization, then the constructs 
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lacking the NT will remain in the cytoplasm, but if it is important for cytoplasmic localization, 
then the construct lacking it will be localized only in the nucleus.  PRMT6 localizes exclusively 
to the nucleus.  If its NT is the reason for this localization, then the chimera bearing its NT will be 
localized exclusively to the nucleus. 
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